etoposide has been researched along with melphalan in 617 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 59 (9.56) | 18.7374 |
| 1990's | 145 (23.50) | 18.2507 |
| 2000's | 202 (32.74) | 29.6817 |
| 2010's | 177 (28.69) | 24.3611 |
| 2020's | 34 (5.51) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Barrows, LR; Ireland, CM; Kokoshka, JM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Erlenkamp, G; Hilgeroth, A; Krug, M; Schächtele, C; Sippl, W; Totzke, F | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hu, W; Huang, XS; Li, X; Li, ZY; Shen, YM; Wu, JF; Yang, L; Zheng, YT | 1 |
| Barlogie, B; Corry, PM; Dosik, G; Freireich, EJ; Hankenson, R; Johnston, DA; Khalil, K; Lawson, R; Lippman, L; Reilly, E; Rigor, B; Tenczynski, TF; Yip, E | 1 |
| Adam, M; Baruchel, A; Brice, P; Dombret, H; Gisselbrecht, C; Lepage, E; Marolleau, JP; Miclea, JM; Sitthy, X | 1 |
| Egerer, G; Ehrhardt, R; Haas, R; Hohaus, S; Hunstein, W; Witt, B | 1 |
| Arya, R; Brito-Babapulle, F; Griffiths, T; Mufti, GJ; Pagliuca, A | 1 |
| Weiss, RB | 1 |
| Crump, M; Keating, A | 1 |
| Biron, P; Blay, JY; Bouffet, E; Brunat-Mentigny, M; Chauvin, F; Clavel, M; Dumontet, C; Meckenstock, R; Philip, I; Philip, T | 1 |
| Copelan, EA | 1 |
| Janmohammed, RM; Leyland, MJ; Long, SG; Macdonald, DF; Milligan, DW; Smith, AG | 1 |
| D'Angio, G; Evans, A; Scher, C | 1 |
| Craft, AW; Gordon, SJ; Pearson, AD; Reid, MM | 1 |
| Corbett, R; Kingston, J; Lewis, I; McElwain, T; Meller, S; Pinkerton, R; Pritchard, J | 1 |
| Gore, M; Harding, M; Mansi, J; Meldrum, M; Milan, S; Perren, T; Selby, P; Treleavan, J; Viner, C; Zulian, G | 1 |
| Cold, S; Pfeiffer, P; Rose, C | 1 |
| Blair, S; Cervi, P; Chopra, R; Goldstone, AH; Kinsey, S; Linch, DC; McMillan, AK; Moir, D; Patterson, KG; Richards, JD | 1 |
| Burdach, S; Dilloo, D; Gadner, H; Göbel, U; Nürnberger, W; Paulussen, M; Peters, C; Voehringer, R; Wernet, P; Wurm, R | 1 |
| Douay, L; Eugene-Jolchine, I; Fouillard, L; Gorin, NC; Isnard, F; Laporte, JP; Najman, A; Stachowiak, J | 1 |
| Brandwein, JM; Crump, M; Keating, A; Scott, JG; Sutcliffe, SB | 1 |
| Bonadonna, G; Bregni, M; Gandola, L; Gianni, AM; Lombardi, F; Siena, S; Valagussa, P | 1 |
| Bastion, Y; Coiffier, B; Tigaud, JD | 1 |
| Bigner, DD; Blum, MR; Dewhirst, MW; Elion, GB; Friedman, HS; Laskowitz, DT; Lilley, ER; Savina, PM; Schold, SC | 1 |
| Cheung, NK; Gulati, SC; Kushner, BH; LaQuaglia, M; Mandell, LR; O'Reilly, RJ | 1 |
| Emminger, W; Emminger-Schmidmeier, W; Gadner, H; Hawliczek, R; Höcker, P; Peters, C | 1 |
| Barlogie, B; Beckord, J; Crowley, J; Pugh, RP; Salmon, SE | 1 |
| Goldstone, A; McMillan, A | 1 |
| Dezube, B; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA | 1 |
| Cheung, NK; Gulati, SC; Heller, G; Kushner, BH; O'Reilly, RJ | 1 |
| Biron, P; Cahn, JY; Colombat, P; Gorin, NC; Herve, P; Lamagnere, JP; Laporte, JP; Philip, T | 1 |
| Aihara, T; Hanada, R; Hayashi, Y; Hirata, A; Imaizumi, S; Inaba, T; Miyakawa, T; Sugawara, T; Yaginuma, A; Yamamoto, K | 1 |
| Bigner, DD; Colvin, OM; Elion, GB; Friedman, HS; Lilley, ER; Rosenberg, MC | 1 |
| Alberts, DS; Asbury, RF; Boros, L; Goodman, TL; Hickox, DE; Peng, YM; Penn, TE | 1 |
| Brandwein, JM; Callum, J; Keating, A; Scott, JG; Sutcliffe, SB | 1 |
| al-Achi, A; Herman, TS; Holden, SA; Teicher, BA | 1 |
| Iwabuchi, M; Takahashi, K | 1 |
| Markman, M | 1 |
| Ardiet, C; Biron, P; Mercatello, A; Philip, T; Tranchand, B | 1 |
| Ash, CM; Earl, HM; Geddes, DM; Goldstone, AH; Hajichristou, HT; Harper, PG; Miles, DW; Souhami, RL; Spiro, SG; Tobias, JS | 1 |
| Benbunan, M; Brouet, JC; Castaigne, S; Cosset, JM; Fermand, JP; Gerota, J; Lévy, Y; Seligmann, M | 1 |
| Bregni, M; Gianni, AM; Siena, S; Tarella, C | 1 |
| Ardiet, C; Navarro, C; Sapet, C; Tranchand, B | 1 |
| Devereaux, S; Goldstone, AH; Gribben, JG; Linch, DC; McMillan, A; Patterson, K | 1 |
| Forgeson, G; Gore, M; McElwain, TJ; Milan, S; Nandi, A; Perren, TJ; Selby, P; Zulian, GB | 1 |
| Bernasconi, C | 1 |
| Alexanian, R; Barlogie, B; Cabanillas, F; Velasquez, WS | 1 |
| Arriagada, R; Baume, D; Beaujean, F; Gouyette, A; Hayat, M; Le Chevalier, T; Ostronoff, M; Pico, JL; Rebattu, P | 1 |
| Peters, W; Souhami, R | 1 |
| Blaise, D; Gaspard, MH; Gastaut, JA; Maraninchi, D; Michel, G; Novakovitch, G; Rossi, JF; Stoppa, AM; Tubiana, N; Weiller, PJ | 1 |
| Hovi, L; Mäkipernaa, A; Maunuksela, EL; Perkkiö, M; Rajantie, J; Siimes, MA; Wikström, S | 1 |
| Huijgens, PC; Ossenkoppele, GJ; Reijneke, RM; Thomas, LL; van der Lelie, J; Wijngaarden, MJ | 1 |
| Beaujean, F; Behard, C; Benhamou, E; Deville, A; Flamant, F; Hartmann, O; Kalifa, C; Lejars, O; Patte, C; Thyss, A | 1 |
| Linch, DC; Singer, CR | 1 |
| Appelbaum, FR; Buckner, CD | 1 |
| Lampkin, BC; Wong, KY | 1 |
| Boll, J; Deicher, H; Essers, U; Gamm, H; Glück, S; Görg, K; Gramatzki, M; Peest, D; Schedel, I; Schmoll, HJ | 1 |
| Gassmann, W; Kayser, W; Löffler, H; Schmitz, N | 1 |
| Dill, PL; Macaluso, CK; Marsden, JA; Weisenthal, LM | 1 |
| Coombs, A; Hanson, J; Moore, JL | 1 |
| Klastersky, J; Sculier, JP | 1 |
| Kaye, SB | 1 |
| Hamblin, T; Loehry, CA; McCullen, M; Parham, DM; Vyas, SK; Winwood, PJ | 1 |
| Lishner, M; Slingerland, J; Sutcliffe, SB; Theresa, C | 1 |
| Alessandrino, EP; Astori, C; Bernasconi, P; Brusamolino, E; Canevari, A; Castelli, G; Lazzarino, M; Morra, E; Orlandi, E; Pagnucco, G | 1 |
| Daguenel, A; Gorin, NC; Laporte, JP; Lesage, S; Najman, A; Parlier, Y; Woler, M | 1 |
| Bassan, R; Bellavita, P; Borleri, GM; Buelli, M; Comotti, B; Cortelazzo, S; Marziali, S; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Chapman, CS; Ghosh, K; Murphy, P; Sivakumaran, M; Wood, JK | 1 |
| Dercksen, MW; Dirkson, MK; Gerritsen, WR; Pinedo, HM; Rodenhuis, S; Schaasberg, WP; Slaper-Cortenbach, IC; van der Schoot, CE; von dem Borne, AE | 1 |
| Dranitsaris, G; Sutcliffe, SB | 1 |
| Kaya, H; Kumabashiri, I; Matsuda, T; Nakamura, S; Ohtake, S; Yamazaki, H | 1 |
| Dreger, P; Haferlach, T; Klöss, M; Loeffler, M; Löffler, H; Petersen, B; Schmitz, N | 1 |
| Bullorsky, EO; Ceresetto, JM; Pest, P; Peters, RA; Shanley, CM; Stemmelin, GR | 1 |
| Crowther, D; Ghielmini, M; Morgenstern, GR; Pettengell, R; Radford, JA; Scheid, C; Stern, PL | 1 |
| Beere, HM; Chapman, RS; Chresta, CM; Dive, C; Heer, S; Herberg, AA; Hickman, JA; Whetton, AD | 1 |
| Baker, TR; Cornelison, TL; Driscoll, DL; Piver, MS | 1 |
| Benos, P; Donnadio, D; Giacalone, PL; Laffargue, F | 1 |
| Dreger, P; Eckstein, V; Haferlach, T; Jacobs, S; Löffler, H; Marquardt, P; Müller-Ruchholtz, W; Mülverstedt, T; Schmitz, N; Suttorp, M | 1 |
| Ballestrero, A; Basta, P; Brema, F; Ferrando, F; Ghio, R; Gobbi, M; Moraglio, L; Patrone, F; Sessarego, M; Valbonesi, M | 1 |
| Bout, M; Brémond, JL; Dayan, A; Delain, M; Domenech, J; Gihana, E; Linassier, C; Petit, A; Petitdidier, C; Truglio, D | 1 |
| Goldstone, AH; Khwaja, A; Linch, DC | 1 |
| Phillips, GL; Reece, DE | 1 |
| Berger, NA; Chatterjee, S; Cheng, MF | 1 |
| Chopra, R; Goldstone, AH; Linch, DC; McMillan, A; Mills, W; Pearce, R | 1 |
| Brice, P; Castaigne, S; Gisselbrecht, C; Marolleau, JP; Pautier, P | 1 |
| Aglietta, M; Bondesan, P; Caracciolo, D; Falda, M; Gallo, E; Gavarotti, P; Locatelli, F; Novarino, A; Paolino, F; Sanavio, F | 1 |
| Bender-Götze, C; Burdach, S; Ebell, W; Friedrich, W; Herrmann, F; Klingebiel, T; Koscielniak, E; Kremens, B; Schmid, H; Siegert, W | 1 |
| Barbot, C; Jazwiec, B; Mahon, FX; Reiffers, J; Rice, A; Vanès, I | 1 |
| Alexanian, R; Champlin, R; Delasalle, K; Dimopoulos, MA; Hester, J | 1 |
| Ciobanu, N; Gray, R; Lazarus, HM; Weiner, RS; Winter, J | 1 |
| Chatterjee, R; Goldstone, AH; Katz, M; McGarrigle, HH; Mills, W | 1 |
| Ito, H; Kimura, Y; Nakamura, H; Nomura, N; Otaka, M; Sakai, N; Shirota, T; Suzuki, A; Toyama, K; Uchida, H | 1 |
| Bezwoda, WR; Dansey, RD; Seymour, LK | 1 |
| Chopra, R; Goldstone, AH; Hancock, B; Hudson, GV; Linch, DC; McMillan, A; Milligan, D; Moir, D; Winfield, D | 1 |
| Cottler-Fox, M; Cowan, K; Dunbar, CE; Goodman, S; Leitman, S; Nienhuis, AW; O'Shaughnessy, J; Quesenberry, P; Sorrentino, BP; Stewart, FM | 1 |
| Dreger, P; Gassmann, W; Glass, B; Haferlach, T; Horst, HA; Löffler, H; Ollech-Chwoyka, J; Schmitz, N; Suttorp, M | 1 |
| Burdach, S; Dilloo, D; Jürgens, H; Körholz, D; Koscielniak, E; Mauz-Körholz, C; Nürnberger, W; Pape, H; Paulussen, M; Peters, C | 1 |
| Brosteanu, O; Haas, R; Hasenclever, D; Kirchner, H; Koch, P; Kuse, R; Lathan, B; Pfreundschuh, MG; Rueffer, U; Schmitz, N | 1 |
| Bonilla, MA; Canete, A; Cheung, IY; Cheung, NK; Heller, G; Kushner, B; Larson, SM; Yeh, SJ | 1 |
| Riley, C; Slavik, M; Wu, J | 1 |
| Dehnen, H; Göbel, U; Jürgens, H; Wessalowski, R; Willnow, U | 1 |
| Chastang, C; Fabre, C; Lebeau, B; Massin, F; Muir, JF; Vincent, J | 1 |
| Jackson, GH; Lennard, AL; Lucraft, H; Proctor, SJ; Taylor, PR | 1 |
| Chopra, R; Goldstone, AH; Linch, DC; McMillan, AK; Patterson, KG; Pearce, R; Taghipour, G; Yuklea, S | 1 |
| Brandwein, J; Couture, F; Crump, M; McCrae, J; Murray, C; Pantalony, D; Scott, JG; Sherret, H; Smith, AM; Sutton, DM | 1 |
| Brauner, R; Devergie, A; Fischer, A; Fontoura, M; Gluckman, E; Griscelli, C; Michon, J; Prevot-Saucet, C; Souberbielle, JC; Zucker, JM | 1 |
| Smith, RJ; Sweetenham, JW | 1 |
| Goldstone, AH; Linch, DC; Mills, W; Strang, J | 1 |
| Lazo, JS; Rusnak, JM | 1 |
| Brandwein, J; Carstairs, K; Colwill, R; Crump, M; Girouard, C; Imrie, K; Keating, A; Pantalony, D; Prince, HM; Scott, JG; Stewart, AK; Sutcliffe, SB; Sutton, DM; Tsang, RW | 1 |
| Calmels, TP; Hoyt, DG; Kondo, Y; Lazo, JS; Rusnak, JM; Yalowich, JC | 1 |
| Bender, JG; Blake, M; Carreon, J; Lee, WJ; Oldham, F; Schilling, M; Smith, S; Swinney, P; Van Epps, D; Williams, DE; Williams, SF; Zimmerman, T | 1 |
| Döhner, H; Flentje, M; Goldschmidt, H; Haas, R; Hunstein, W; Möhle, R; Moos, M; Murea, S; Wannenmacher, M; Witt, B | 1 |
| Ager, S; Baglin, TP; Bass, G; Mahendra, P; Marcus, RE; Richards, EM | 1 |
| Cowan, KH; Gudas, JM; Li, T; Nguyen, H; Robey, R; Sadzewicz, L; Wosikowski, K | 1 |
| Benhamou, E; Bonnay, M; Couanet, D; Hartmann, O; Plantaz, D; Pondarré, C; Valteau-Couanet, D; Vassal, G | 1 |
| Ager, S; Baglin, TP; Barker, P; Bass, G; Bloxham, DM; Boraks, PA; Hood, IM; Jestice, HK; Johnson, D; Mahendra, P; Marcus, RE; Scott, MA | 1 |
| Garćia, J; Grañena, A; Palou, J; Sarrá, J; Valls, A; Vivancos, P | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Buelli, M; Comotti, B; Cortelazzo, S; Fracassetti, D; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Bonini, A; Carotenuto, M; Cascavilla, N; D'Arena, G; Di Mauro, L; Greco, MM; Melillo, L; Minervini, MM; Musto, P; Sajeva, MR; Scalzulli, P | 1 |
| Haynes, AP; Iqbal, A; McQuaker, IG; Russell, NH | 1 |
| Mahendra, P; Marcus, RE; Nacheva, E; Richards, EM; Sinclair, P | 1 |
| Gaarsdal, E; Jensen, L; Johnsen, HE; Knudsen, LM; Nielsen, KJ; Nikolaisen, K | 1 |
| Fielding, AK; Goldstone, AH; Jamieson, E; Linch, DC; Sullivan, AM; Watts, MJ | 1 |
| McMillan, R; Meisenberg, BR; Miller, WE | 1 |
| Bargou, R; Dörken, B; Hildebrandt, M; Körner, IJ; Krahl, D; Mapara, MY; Reichardt, P | 1 |
| Anderson, E; Anderson, T; Cameron, DA; Chetty, U; Craig, J; Dixon, M; Gabra, H; Hawkins, A; Jack, W; Kunkler, I; Lee, L; Leonard, R; Leonard, RC; MacKay, J; Matheson, L; Miller, W; Parker, AC | 1 |
| Berdel, WE; Hoppe, B; Knauf, WU; Koenigsmann, MP; Notter, M; Oberberg, D; Reufi, B; Thiel, E | 1 |
| Behringer, D; Fetscher, S; Finke, J; Kanz, L; Lange, W; Lübbert, M; Mertelsmann, R | 1 |
| Barbui, T; Bertini, M; Botto, B; Cinieri, S; Cortellazzo, S; Falda, M; Freilone, R; Grignani, F; Levis, A; Liberati, AM; Locatelli, F; Lovisone, E; Marmont, F; Pizzuti, M; Resegotti, L; Rossi, A; Viero, P; Vitolo, U | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Comotti, B; Cortelazzo, S; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Amigo, ML; Caballero, MD; del Cañizo, C; García, R; Gonzalez, M; Hernández, JM; San Miguel, JF; Vazquez, L | 1 |
| Benedetti Panici, P; Caracussi, U; Foddai, ML; Leone, G; Mancuso, S; Maneschi, F; Menichella, G; Pierelli, L; Salerno, MG; Scambia, G; Serafini, R; Vittori, M | 1 |
| Hanada, R; Hongo, T; Horikoshi, Y; Sakurai, M; Yajima, S | 1 |
| Betts, E; Goebel, ME; Honegger, H; Jost, LM; Nagler, A; Stahel, RA | 1 |
| Ascensao, JL; Fontelonga, A; Hall, S; Kelly, AJ; MacKintosh, FR; Monroe, P; Ruthven, A; Shaft, D; Wilson, GS | 1 |
| Bartels, H; Dreger, P; Glass, B; Kuse, R; Löffler, H; Schmitz, N; Sonnen, R; Uharek, L; von Neuhoff, N | 1 |
| Mizoguchi, H; Wada, M | 1 |
| Brandwein, J; Crump, M; Dufresne, J; Girouard, C; Imrie, K; Keating, A; Pantolony, D; Prince, HM; Stewart, AK | 1 |
| Abella, E; Adams, PT; al-Katib, A; Dragovic, J; Du, W; Janakiraman, N; Karanes, C; Raman, SB; Ratanatharathorn, V; Sensenbrenner, L; Silver, SM; Uberti, J; Varterasian, M | 1 |
| Cassileth, P; Cooper, BW; Fernandez, H; Kutteh, L; Lazarus, HM; Miller, KB; Morelli, J; Pecora, AL; Roitman, D; Schenkein, DP; Stadtmauer, E | 1 |
| Barbui, T; Bellavita, P; Cortelazzo, S; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Kortmann, RD | 1 |
| de Wolf, JT; Hovenga, S; Klip, H; Vellenga, E | 1 |
| Andreeva, LA; Batan, ZE; Chervonobab, IuV; Chimishkian, KL; Demina, EA; Kondrat'eva, NE; Larionova, VB; Milanovich, NF; Mkheidze, DM; Ptuskin, VV; Snegir', VM; Tupitsyn, NN; Uss, AL; Zmachinskiĭ, VA | 1 |
| Allavena, P; Broggini, M; Colella, G; D'Incalci, M; Giardina, G; Sen, S | 1 |
| Buckley, J; Cairo, M; Feig, S; Harris, RE; Matthay, K; Ozkaynak, MF; Reynolds, CP; Seeger, RC; Villablanca, JG | 1 |
| Crump, M; Dubé, I; Girouard, C; Imrie, KR; Keating, A; Prince, HM | 1 |
| Aebi, S; Fink, D; Haas, M; Howell, SB; Kim, HK; Nebel, S; Norris, PS | 1 |
| Keshelava, N; Reynolds, CP; Seeger, RC | 1 |
| Barlogie, B; Bracy, D; Desikan, KR; Fassas, A; Jagannath, S; Mattox, S; Mehta, J; Munshi, N; Nelson, J; Siegel, D; Singhal, S; Tindle, S; Tricot, G; Vesole, DH | 1 |
| Diehl, V; Engert, A; Josting, A; Kàtay, I; Rueffer, U; Tesch, H; Wickramanayake, PD; Winter, S | 1 |
| Hoffmann, HD; Hormes, P; Lutz, WK; Vamvakas, S; Vock, EH | 1 |
| Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Pharo, A; Smeland, EB | 1 |
| Buckner, CD; Weaver, CH; Zhen, B | 1 |
| Dreger, P; Glass, B; Kuse, R; Löffler, H; Schmitz, N; Schoch, R; Sonnen, R; Uharek, L; von Neuhoff, N | 1 |
| Bulabois, CE; Colombat, P; Dupas, B; Harousseau, JL; Juge-Morineau, N; Mahé, B; Milpied, N; Moreau, A; Moreau, P; Rapp, MJ; Voillat, L | 1 |
| Cunningham, D; Popescu, RA; Wotherspoon, AC | 1 |
| Blumenstengel, K; Fricke, HJ; Höffken, K; Kath, R; Kunert, C; Sayer, HG; Vogel, W | 1 |
| Andreu, G; Aoudjhane, M; Bauters, F; Belkacemi, Y; Cheron, N; Douay, L; Fenaux, P; Fouillard, L; Gorin, NC; Isnard, F; Jouet, JP; Labopin, M; Laporte, JP; Lemonnier, MP; Lesage, S; Lopez, M; Morel, P; Najman, A; Noël-Walter, MP; Stachowiak, J; Zunic, P | 1 |
| Fehse, N; Gutensohn, K; Hassan, HT; Kröger, N; Krüger, W; Lölliger, C; Zander, AR; Zeller, W | 1 |
| Baranzelli, MC; Bergeron, C; Boutard, P; Frappaz, D; Gentet, JC; Hartmann, O; Michon, J; Pein, F; Philip, T; Quintana, E; Stephan, JL; Thyss, A; Tournade, MF; Valteau-Couanet, D; Vannier, JP; Zucker, JM | 1 |
| Aebi, S; Fink, D; Fink, JL; Gordon, R; Howell, SB; Kim, HK; Zheng, H | 1 |
| Anaissie, E; Ayers, D; Barlogie, B; Cheson, B; Cromer, J; Crowley, J; Desikan, KR; Dhodapkar, D; Epstein, J; Fassas, A; Jagannath, S; Mattox, S; Mehta, J; Munshi, N; Naucke, S; Sawyer, J; Siegel, D; Singhal, S; Spoon, D; Tricot, G; Vesole, D | 1 |
| Cavalli, F; Ghielmini, M; Sanna, P; Van den Bosch, S | 1 |
| Balmelli, T; Eppenberger, H; Filippini, G; Soldati, G | 1 |
| Bamborschke, S; Diehl, V; Feiden, W; Lehrke, R; Re, D; Schröder, R; Tesch, H | 1 |
| Crump, M; Gospodarowicz, MK; Keating, A; Sutcliffe, SB; Tsang, RW | 1 |
| Dias Wickramanayake, P; Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Scheid, C; Tesch, H; Wolf, J | 1 |
| Boente, P; Costa, LJ; del Giglio, A; Luzzi, JR; Mota, A; Neves, P; Pinczowski, H; Sampaio, C; Varella, PC | 1 |
| Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D | 1 |
| Hovi, L; Lipsanen, M; Saarinen-Pihkala, UM; Tapanainen, P; Vettenranta, K | 1 |
| Foss, HD; Keilholz, U; Knauf, W; Siehl, J; Szelényi, H; Thiel, E | 1 |
| Bourhis, JH; Brice, P; Brousse, N; Decaudin, D; Gisselbrecht, C; Haioun, C; Morel, P; Quesnel, B; Souleau, B; Van Hoof, A | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Caldera, D; Colombo, A; Klersy, C; Malcovati, L; Martinelli, G; Nascimbene, C; Varettoni, M; Vitulo, P; Volpini, E | 1 |
| Clarke, NJ; Kira, J; Nakabeppu, Y; Naylor, S; Nishioka, K; Ohyagi, Y; Tomlinson, AJ; Yamada, T; Younkin, SG | 1 |
| Gregora, E; Havrdová, E; Kobylka, P; Kozák, T; Maaloufová, J; Marecková, H; Pit'ha, J; Pytlík, R; Vodvárková, S | 1 |
| Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Rueffer, U; Söhngen, D; Tesch, H; Wickramanayake, PD; Wolf, J | 2 |
| Caracciolo, D; Corradini, P; Cuttica, A; Gavarotti, P; Ladetto, M; Novero, D; Pileri, A; Rossi, G; Tarella, C; Zallio, F | 1 |
| Abdallah, A; Haas, R; Ho, AD; Hohaus, S; Martin, S; Schlenk, RF; Voso, MT | 1 |
| Buthmann, U; Freund, M; Kleine, HD; Volk, J | 1 |
| Angrilli, F; Ascari, E; Bertè, R; Broglia, C; Cavanna, L; Di Renzo, N; Ghirardelli, ML; Gobbi, PG; Iannitto, E; Molica, S; Petrilli, MP | 1 |
| Bardou, VJ; Bertucci, F; Delpero, JR; Faucher, C; Houvenaeghel, G; Maraninchi, D; Viens, P | 1 |
| Clowes, C; Duarte, R; Pu, QQ; Wang, X | 1 |
| Argiris, A; Cooper, DL; Seropian, S | 1 |
| Brown, CB; Chaudhry, A; deMetz, C; Glück, S; Guo, D; Klassen, J; Morris, D; Russell, JA; Stewart, DA | 1 |
| Dzhumabaeva, BT; Efimov, IV; Kaplanskaia, IB; Margolin, OV; Moiseeva, TN; Pivnik, AV; Rasstrigin, NA; Roshchina, LS; Shavlokhov, VS; Sotnikov, VM; Stroiakovskiĭ, DL | 1 |
| de Vries, P; Singer, JW | 1 |
| Ballestrero, A; Clavio, M; Ferrando, F; Garuti, A; Ghio, R; Gobbi, M; Gonella, R; Patrone, F; Sessarego, M | 1 |
| Carreras, E; Esteve, J; Fernández, F; Martínez, C; Montserrat, E; Perales, M; Rovira, M; Urbano-Ispizua, A | 1 |
| Harada, N; Hata, H; Matsuzaki, H; Otsuki, T; Ueki, A; Wada, H; Yamada, O; Yata, K; Yawata, Y | 1 |
| Jantunen, E; Mahlamäki, E; Nousiainen, T | 1 |
| Blume, KG; Hoppe, RT; Horning, SJ; Hu, WW; Johnston, LJ; Negrin, RS; Stockerl-Goldstein, KE | 1 |
| Blaise, D; Caraux, J; Chabannon, C; Faucher, C; Maraninchi, D; Vey, N | 1 |
| Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M | 1 |
| Dobie, D; Hastings, M; Mahendra, P; Richardson, G; Tauro, S | 1 |
| Goh, YT; Hwang, YK; Linn, YC; Tan, CH; Tan, HC | 1 |
| Klener, P; Procházka, B; Slabý, J; Trnený, M | 1 |
| Kushner, BH; Meyers, PA | 1 |
| Aplan, PD; Ploski, JE | 1 |
| Benboubker, L; Colombat, P; Dugay, J; Gauvain, JB; Goupille, P; Linassier, C; Lucas, V; Luthier, F; Maigre, M; Rodon, P | 1 |
| Bouafia, F; Coiffier, B; Dumontet, C; Espinouse, D; Hequet, O; Salles, G; Thieblemont, C | 1 |
| Beham-Schmid, C; Hoefler, G; Linkesch, W; Neumeister, P; Sill, H | 1 |
| Aleĭnikova, OV; Batan, ZE; Dziuba, EV; Milanovich, NF; Mitskevich, PB; Skriagin, AE; Solov'eva, NS; Uss, AL; Vlasenkova, SV; Zavgorodniaia, IL; Zhavrid, EA; Zmachinskiĭ, VA | 1 |
| Abraham, R; Chen, CI; Crump, M; Keating, A; Stewart, AK; Tsang, R | 1 |
| Gregora, E; Havrdová, E; Kobylka, P; Kozák, T; Maaloufová, J; Pit'ha, J; Pytlík, R; Vodvárková, S | 1 |
| Baker, DL; Chan, KW; Davis, JH; Dickman, PS; Gerbing, RB; Gorlick, RG; Grovas, A; Herzog, CE; Krailo, MD; Ladanyi, M; Lindsley, KL; Liu-Mares, W; Meyers, PA; Nachman, JB; Sailer, SL; Sieger, L; Wadman, J | 1 |
| Diehl, V; Ehninger, G; Franklin, J; Hasenclever, D; Kirchner, H; Koch, P; Lathan, B; Loeffler, M; Pfreundschuh, M; Rueffer, U; Schmitz, N; Sextro, M; Tesch, H | 1 |
| Ferrandina, G; Greggi, S; Leone, G; Mancuso, S; Menichella, G; Pierelli, L; Salerno, MG; Scambia, G | 1 |
| Filippi, M; Gualandi, F; Inglese, M; Lugaresi, A; Mancardi, GL; Marmont, A; Marrosu, MG; Massacesi, L; Meucci, G; Murialdo, A; Pagliai, F; Saccardi, R; Sardanelli, F; Sormani, MP | 1 |
| Berthold, F; Gahr, M; Hero, B; Hunneman, DH | 1 |
| Chen, P; Gomer, CJ; Keshelava, N; Luna, MC; Reynolds, CP; Triche, TJ; Waidyaratne, SN; Zuo, JJ | 1 |
| Dreger, P; Glass, B; Kuse, R; Schmitz, N; Seyfarth, B; Sonnen, R | 1 |
| Baum, C; Fodstad, Ø; Hildinger, M; Lorico, A; Rappa, G | 1 |
| Bloomer, WD; Ji, M; Papadopoulou, MV | 1 |
| Aller, P; de Blas, E; Fernández, C; Sancho, P; Troyano, A | 1 |
| Ansén, S; Bischoff, S; Bohlen, H; Diehl, V; Dietlein, M; Re, D; Scheidhauer, K; Schicha, H; Tesch, H; Weihrauch, MR; Wolf, J | 1 |
| Aulagner, G; Bertrand, Y; Bleyzac, N; Dai, Q; Galambrun, C; Janoly, A; Jelliffe, RW; Magron, P; Maire, P; Martin, P; Souillet, G | 1 |
| Blystad, AK; Delabie, J; Holte, H; Kvalheim, G; Kvaløy, S; Smeland, E | 1 |
| Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K | 1 |
| Berger, F; Brice, P; Colin, P; Diviné, M; Fermé, C; Jaubert, J; Lederlin, P; Mounier, N; Reman, O; Salles, G; Stamatoullas, A; Voillat, L | 1 |
| Berger, NA; Chatterjee, S; Gosky, D; Hirota, H | 1 |
| Becherer, A; Dudczak, R; Greinix, HT; Jaeger, U; Kalhs, P; Karanikas, G; Kletter, K; Mitterbauer, M; Pötzi, C; Raderer, M | 1 |
| Ariatti, C; Bertini, M; Boccomini, C; Botto, B; Calvi, R; Capello, D; Carbone, A; Freilone, R; Gaidano, G; Gallo, E; Gloghini, A; Milan, I; Novero, D; Orsucci, L; Palestro, G; Parvis, G; Pregno, P; Saglio, G; Vitolo, U; Vivenza, D; Zagonel, V | 1 |
| Hayashi, Y; Iinuma, K; Imaizumi, M; Ito, E; Kikuta, A; Konno, T; Ohi, R; Shimizu, T; Takano, T; Tsuchiya, S; Watanabe, A | 1 |
| Anderson, JR; Barr, FG; Crist, WM; Donaldson, SS; Maurer, HM; Pappo, AS; Qualman, SJ; Raney, RB; Wiener, ES | 1 |
| Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M | 1 |
| Dreger, P; Glass, B; Haas, R; Kneba, M; Kröger, N; Kuse, R; Martin, S; Parwaresch, R; Schmitz, N; Sonnen, R | 1 |
| Barbui, T; Bassan, R; Carter, M; Casula, P; Di Bona, E; Fabris, P; Lambertenghi-Deliliers, G; Lerede, T; Lister, TA; Morandi, S; Pogliani, E; Rambaldi, A; Rohatiner, AZ; Rossi, G | 1 |
| Braun, T; Ferrara, JL; Hubers, D; Hutchinson, RJ; Levine, JE; Matthay, KK; Shapiro, B; Shulkin, BL; Sisson, JC; Spalding, S; Yanik, GA | 1 |
| Alloisio, M; Balzarotti, M; Bertuzzi, A; Castagna, L; Compasso, S; Nozza, A; Quagliuolo, V; Santoro, A; Siracusano, L; Soto Parra, H | 1 |
| Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V | 1 |
| Balleari, E; Ballestrero, A; Clavio, M; Ferrando, F; Garuti, A; Ghio, R; Gobbi, M; Gonella, R; Grasso, R; Miglino, M; Patrone, F | 1 |
| Boissevain, F; Carella, AM; Decker, S; Diehl, V; Goldstone, AH; Haenel, M; Hasenclever, D; Kirchner, H; Koch, B; Lohri, A; Müller, P; Pfistner, B; Schmitz, N; Sextro, M; Sieber, M; Zschaber, R | 1 |
| Clemente González, C; García Parés, D; García-Bragado Dalmau, F; Guardia Sánchez, R; Pérez Ayuso, MJ; Porcar Ramells, C | 1 |
| Elonen, E; Franssila, K; Itälä, M; Jantunen, E; Kuittinen, O; Lehtinen, T; Oinonen, R; Wiklund, T | 1 |
| Byrne, J; Carter, GI; Craddock, CF; Cull, GM; Garg, M; Haynes, AP; Lui Yin, JA; Lush, RJ; Mahendra, P; Mufti, G; Pagliuca, A; Parker, JE; Potter, MN; Prentice, HG; Russell, NH | 1 |
| Gallet, B; Genet, P; Jondeau, K; Laribi, K; Lionnet, F; Pulik, M; Touahri, T | 1 |
| Baccarani, M; Benni, M; Cavo, M; Cellini, C; Fiacchini, M; Gozzetti, A; Ronconi, S; Tosi, P; Tura, S; Zamagni, E | 1 |
| Engert, A; Glossmann, JP; Josting, A; Paulus, U; Pfistner, B | 1 |
| Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
| Hazenberg, BP; Jager, PL; Smit, JW; van Gameren, II; Vellenga, E | 1 |
| Abel, U; Baudis, M; Birkmann, J; Bischoff, HG; Franke, A; Grundeis, M; Havemann, K; Hossfeld, DK; Kaiser, U; Karakas, T; Kneba, M; Köppler, H; Krahl, D; Mantovani, L; Mesters, RM; Metzner, B; Müller, P; Parwaresch, R; Pfab, R; Pfreundschuh, M; Reiser, M; Rothmann, F; Schmalenberg, H; Schmitz, N; Schumacher, K; Steinhauer, EU; Trümper, L; Uebelacker, I; von Seydewitz, CU | 1 |
| Berger, C; Bernard, JL; Coze, C; Frappaz, D; Michon, J; Perol, D; Philip, T; Zucker, JM | 1 |
| Buglova, SE; Ismail-zade, RS; Potapnev, MP; Rud'ko, VS; Sachivko, NV; Semenov, AS; Shman, TV; Zhavrid, EA | 1 |
| Finckenstein, FG; Graf, N; Gruhn, B; Hasan, C; Hero, B; Klingebiel, T; Koscielniak, E; Kremens, B; Laws, HJ; Niemeyer, C; Schulz, A; Selle, B; Wawer, A; Zintl, F | 1 |
| Albó, C; Arranz, R; Caballero, MD; Cabrera, R; Carreras, E; Conde, E; Fernández de Sevilla, A; Gandarillas, M; García Ruíz, JC; García-Conde, J; García-Laraña, J; Grande, C; Iriondo, A; Lahuerta, JJ; Marín, J; Moraleda, JM; Pérez-Equiza, C; Pérez-Simón, JA; Rifón, J; Rubio, V; San Miguel, JF; Sierra, J; Sureda, A; Varela, R; Vidal, MJ; Zuazu, J | 1 |
| Afanas'ev, BV; Alekseeva, IuA; Medvedeva, NV; Mikhaĭlova, NB; Zaritskiĭ, AIu; Zubarovskaia, LS | 3 |
| Brunetto, AL; de Almeida, SG; de Castro, CG; Gregianin, LJ; Loss, JF; Rivero, LF; Schwartsmann, G | 1 |
| Aizawa, M; Dohi, N; Gono, T; Hoshi, K; Ikeda, S; Koike, K; Matsuda, M; Sakashita, K; Tada, T | 1 |
| del Palacio, A; Garau, M; Molina, L; Relaño, MT | 1 |
| Crump, M; Keating, A; Mollee, P; Song, KW | 1 |
| Cooney, JP; Parthasarathy, M; Stiff, PJ; Toor, AA | 1 |
| Briggs, A; Chow, HH; Dorr, RT; Kintzel, P; List, A; Meyers, R | 1 |
| Barbui, T; Boccadoro, M; Cortelazzo, S; Coser, P; Cuttica, A; De Crescenzo, A; Di Nicola, M; Di Renzo, N; Federico, M; Gallamini, A; Gallo, E; Gianni, AM; Levis, A; Liberati, M; Musso, M; Pavone, E; Pescarollo, A; Pileri, A; Pregno, P; Romano, R; Rosanelli, C; Rosato, R; Santini, G; Tarella, C; Vitolo, U | 1 |
| Burdach, S; Dunst, J; Finke, R; Gadner, H; Göbel, U; Haase, R; Haerting, J; Juergens, H; Laws, HJ; Metzner, B; Meyer-Bahlburg, A; Pape, H; van Kaik, B; Wawer, A | 1 |
| Jantunen, E; Kuittinen, T; Nousiainen, T | 1 |
| NEU, JT | 1 |
| AMALRIC, R; CLEMENT, R | 1 |
| GIAUX, G; SWYNGEDAUW, J; TOISON, G | 1 |
| BOWMAN, DE | 1 |
| BACHMAN, CH; DAVIS, HW; GELORMINI, OJ | 1 |
| FRANKE, H | 1 |
| FETZER, H | 1 |
| QUICK, D; RICHMOND, JD | 1 |
| FLATBY, J; MAUDAL, S | 1 |
| RAMIOUL, H | 1 |
| SMITH, IH | 1 |
| ARDRAN, GM; CROOKS, HE | 1 |
| MARX, P | 1 |
| DE VULPIAN, P | 1 |
| KOHN, HI | 1 |
| PIGNATARO, E | 1 |
| CHAUNDY, CJ | 1 |
| EBERL, J | 1 |
| ECKER, A | 1 |
| SAKUMA, S; TAKAHASHI, S | 1 |
| HENCEK, M; ZACHAR, J | 1 |
| BESKA, F; BRUCKNER, L; CERNY, J | 1 |
| MAHFOUZ, MM | 1 |
| Au, WY; Chan, EC; Kwong, YL; Leung, AY; Liang, R; Lie, AK; Ooi, GC; Siu, LL | 1 |
| Awedan, A; Blajer, B; Król, M; Rokicka, M; Torosian, T; Urbanowska, E; Wiktor-Jedrzejczak, W | 1 |
| Alfaro, PA; Goto, H; Kohn, DB; Pepper, KA; Petersen, D; Reynolds, CP; Yang, B | 1 |
| Abrey, LE; Anderson, ND; Caron, D; Correa, DD; Crump, M; DeAngelis, LM; Forsyth, P; Mason, WP; Moskowitz, CH; Nimer, SD; Paleologos, N; Stewart, D; Zelenetz, A | 1 |
| Arranz, R; Caballero, MD; Carreras, E; Conde, E; Fernández de Sevilla, A; Gandarillas, M; García-Laraña, J; Gutiérrez, A; Lahuerta, JJ; León, A; Marín, J; Rifon, J; Rodríguez, J; SanMiguel, J; Sureda, A; Varela, R; Zuazu, J | 1 |
| Bonneau, AM; Georges, E; Roy, MO; Serfass, L; Wang, Y; Wong, J | 1 |
| ROSWIT, B | 1 |
| Califaretti, N; Crump, M; Gupta, V; Keating, A; Mollee, P; Reddy, V; Song, K; Tsang, R | 1 |
| Blystad, AK; Delabie, J; Holte, H; Ikonomou, I; Kvalheim, G; Kvaløy, S; Vålerhaugen, H | 1 |
| Cejka, P; Jiricny, J; Papouli, E | 1 |
| Campbell, AD; Cohn, SL; Duerst, R; Geissler, G; Haut, PR; Kalapurakal, J; Kletzel, M; Marymount, M; Morgan, E; Rademaker, A; Reynolds, M; Seshadri, R | 1 |
| Ball, ED; Bashey, A; Carrier, E; Chen, YA; Corringham, S; Holman, P; Wang, EH | 1 |
| Cailliot, C; Fouillard, L; Gorin, NC; Isnard, F; Labopin, M; Laporte, JP; Lesage, S; Najman, A; Yeshurun, M | 1 |
| Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA | 1 |
| Alessandrino, EP; Banfi, L; Barbarano, L; Cairoli, R; Corso, A; De Paoli, A; Fava, S; Ferrari, D; Fiumanò, M; Frigerio, G; Isa, L; Klersy, C; Lazzarino, M; Luraschi, A; Mangiacavalli, S; Morra, E; Perego, D; Pinotti, G; Savarè, M; Ucci, G; Uziel, L; Vergani, C; Vismara, A; Zappasodi, P | 1 |
| WOOD, CA | 2 |
| Caplin, M; Friedmann, B; Hartley, JA; Hochhauser, D | 1 |
| Ardito, R; Cammarota, A; Di Renzo, N; Gallucci, G; Romano, G; Tartarone, A | 1 |
| Armitage, JO; Bierman, PJ; Bociek, G; Enke, C; Hankins, J; Lynch, JC; Vose, JM | 1 |
| Dörken, B; Hildebrandt, B; Lippek, F; Mapara, MY; Oertel, S; Plotkin, M; Riess, H; Royer-Pokora, B; Schumacher, V; Trappe, RU; Zuber, J | 1 |
| Berdel, WE; Diehl, V; Dörken, B; Engert, A; Glossmann, JP; Hossfeld, DK; Josting, A; Kirchner, HH; Kisro, J; Mapara, M; Metzner, B; Rudolph, C; Sieber, M; Sienawski, M; Sieniawski, M | 1 |
| Caballero, MD; del Cañizo, MC; López-Holgado, N; Martín, A; Pérez-Simón, JA; San Miguel, JF; Vázquez, L | 1 |
| Abboud, CN; Bernstein, SH; Chapman, M; Friedberg, JW; Ifthikharuddin, JJ; Johnson, V; Lancet, JE; Liesveld, JL; Phillips, GL; Spreng, E; Vesole, DH | 1 |
| Bocková, J; Bystrická, E; Koza, V; Misaniová, L; Pavlicová, V; Scudlová, J; Valentová, D; Vokurka, S | 1 |
| Acholonu, S; Anderlini, P; Champlin, RE; Couriel, D; De Lima, M; Donato, ML; Fayad, L; Giralt, S; Hosing, C; Jones, R; Khouri, IF; Korbling, M; Maadani, F; Manning, JT; McLaughlin, P; Okoroji, GJ; Pro, B; Saliba, RM; Shpall, E; Younes, A | 1 |
| Alapetite, C; Anract, P; Babinet, A; Barthier, S; de Pinieux, G; Laurence, V; Palangié, T; Pierga, JY; Pouillart, P | 1 |
| Diehl, V; Dörken, B; Engert, A; Glossmann, JP; Josting, A; Kisro, J; Ko, Y; Mapara, M; Metzner, B; Nogova, L; Peters, N; Sieniawski, M; Staak, O | 1 |
| Abboud, CN; Felgar, R; Komrokji, RS; Oliva, JL; Zand, M | 1 |
| Arnaud, P; Bocaccio, C; Bourhis, JH; Carde, P; Ferme, C; Jabbour, E; Koscielny, S; Peslin, N; Ribrag, V; Vantelon, JM | 1 |
| Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R | 1 |
| Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R | 1 |
| Brevet, M; Damaj, G; Garidi, R; Gruson, B; Royer, B; Vaida, I | 1 |
| Angelucci, E; Baldini, L; Bordonaro, R; Broglia, C; Cavanna, L; Chisesi, T; Deliliers, GL; Federico, M; Gobbi, PG; Levis, A; Liberati, M; Merli, F; Pavone, V; Santini, G; Stelitano, C; Vitolo, U | 1 |
| Brody, JR; Cunningham, SC; DeMarzo, AM; Dezentje, DA; Gallmeier, E; Hruban, RH; Isacoff, WH; Kern, SE; Offerhaus, GJ; Swartz, MJ; van der Heijden, MS | 1 |
| Cottler-Fox, M; Fassas, A; Fenton, R; French, T; Gojo, I; Guo, C; Heyman, M; Meisenberg, B; Murthy, A; Philips, GL; Rapoport, AP; Ruehle, K; Sarkodee-Adoo, C; Takebe, N; Tan, M; Tricot, G | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Nagy, T; Pintilie, M; Tsang, R | 1 |
| Franc, B; Groshen, S; Horn, B; Maris, JM; Matthay, KK; Reynolds, CP; Seeger, RC; Tan, JC; Twomey, E; Veatch, J; Villablanca, JG; Yanik, GA | 1 |
| Cheung, IY; Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 1 |
| Bahlis, N; Balogh, A; Brown, C; Jones, A; Morris, DG; Russell, JA; Savoie, L; Stewart, DA; Valentine, K | 1 |
| Bystrická, E; Koza, V; Misaniová, L; Pavlicová, V; Scudlová, J; Valentová, D; Visokaiová, M; Vokurka, S | 1 |
| Kunihiko, M; Mariko, Y; Shinichiro, O; Yasuo, I; Yusuke, T; Yutaka, H | 1 |
| Gisselbrecht, C; Hagberg, H | 1 |
| Driver, D; Kilby, AM; McTiernan, A; Michelagnoli, MP; Whelan, JS | 1 |
| Atkins, H; Bence-Bruckler, I; Bredeson, C; Huebsch, L; Leger, C; McDiarmid, S; Sabloff, M; Zhang, H | 1 |
| Cantu-Rodríguez, O; Gomez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, H; Herrera-Garza, J; Jaime-Pérez, J; Mancias-Guerra, C | 1 |
| Caballero, D; Canales, MA; Hernandez-Navarro, F; Martin, A | 1 |
| Chou, T; Han, LN; Hirose, T; Imai, Y; Ishiguro, T; Zhou, J | 1 |
| Hasegawa, Y; Katsuoka, Y; Katsura, Y; Kojima, H; Nagasawa, T; Suzukawa, K; Suzuki, S | 1 |
| Blechschmidt, M; Bornhäuser, M; Ehninger, G; Hänel, M; Hölig, K; Kroschinsky, F; Oelschlaegel, U; Ordemann, R; Platzbecker, U; Poppe-Thiede, K; Schaich, M | 1 |
| Gokhalé, P; Morrison, MJ; Patel, T; Vissers, MC | 1 |
| Cupelli, L; de la Rubia, J; Jarque, I; Jiménez, C; Lorenzo, I; Martín, G; Martínez, JA; Puig, N; Remigia, MJ; Sanz, GF; Sanz, J; Sanz, MA | 1 |
| Kansu, E; Kars, A; Koc, Y; Oyan, B; Ozdemir, E; Tekuzman, G; Turker, A | 1 |
| Berdel, WE; Frickhofen, N; Haas, R; Heimpel, H; Hinke, A; Hossfeld, DK; Kreienberg, R; Kuhn, W; Möbus, V; Opri, F; Sandherr, M; Schneeweiss, A; Thomssen, C | 1 |
| Balzarotti, M; Bramanti, S; Castagna, L; Magagnoli, M; Mazza, R; Nozza, A; Russo, F; Santoro, A; Sarina, B; Siracusano, L; Timofeeva, I; Todisco, E | 1 |
| Clutter, SD; Fortney, JE; Gibson, LF | 1 |
| Avalos, B; Benson, DM; Blum, W; Copelan, E; Elder, PJ; Farag, SS; Lin, TS; Penza, S | 1 |
| Dörken, B; Dreyling, M; Forstpointner, R; Freund, M; Ganser, A; Hiddemann, W; Hoster, E; Huber, C; Ludwig, WD; Nickenig, C; Trümper, L; Unterhalt, M | 1 |
| Bishton, MJ; Haynes, AP | 1 |
| Amitani, Y; Hashimoto, C; Hyo, R; Kobayashi, S; Maruta, A; Motomura, S; Sakai, R; Tamura, T; Tanaka, M | 1 |
| Chantry, AD; Craddock, C; Craig, JI; Marks, DI; Orchard, K; Pearce, RM; Peggs, K; Roddie, C; Snowden, JA; Towlson, KE | 1 |
| Delgado-Lamas, JL; García-Ruiz-Esparza, MA; Gómez-Almaguer, D; Gómez-Rangel, D; Gutiérrez-Aguirre, CH; Morales-Toquero, A; Padilla-González, Y; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Vela-Ojeda, J | 1 |
| Al Harbi, T; Al-Faris, N; Doyle, J; Gassas, A; Goia, C; Pappo, A | 1 |
| Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A | 1 |
| Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM | 1 |
| Atta, J; Chow, KU; Hoelzer, D; Martin, H; Mitrou, PS; Weidmann, E | 1 |
| Arber, C; Bucher, C; Buser, AS; Ghielmini, M; Gratwohl, A; Halter, J; Heim, D; Lohri, A; Meyer-Monard, S; Passweg, JR; Stern, M; Stussi, G; Tichelli, A | 1 |
| Attarbaschi, A; Fritsch, G; Gadner, H; Lawitschka, A; Lion, T; Matthes-Martin, S; Minkov, M; Mittheisz, E; Steiner, M; Zoubek, A | 1 |
| Cheng, S; Evans, WK; Shepherd, FA; Stys-Norman, D | 1 |
| Abdelkefi, A; Ben Abdeladhim, A; Ben Othman, T; Ladeb, S; Lakhal, A; Torjman, L | 1 |
| Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S | 1 |
| Boccadoro, M; Bregni, M; Cabras, A; Calvi, R; Caracciolo, D; Comino, A; Corradini, P; Devizzi, L; Di Nicola, M; Fornari, A; Gallamini, A; Gianni, AM; Ladetto, M; Magni, M; Majolino, I; Mirto, S; Novero, D; Patti, C; Pescarollo, A; Ponzoni, M; Remotti, D; Rosato, R; Stella, M; Tarella, C; Zanni, M; Zoli, V | 1 |
| Aoyama, T; Hagiwara, S; Imataki, O; Inoue, N; Kataoka, T; Katsumata, M; Katsuta, T; Kawakami, K; Mochizuki, T; Motokawa, S; Tamai, Y; Yoshida, T | 1 |
| Al-Ali, HK; Niederwieser, D; Wittekind, C | 1 |
| Gullbo, J; Johnsen, JI; Kogner, P; Larsson, R; Lewensohn, R; Lindskog, M; Lövborg, H; Ponthan, F; Segerström, L; Sveinbjörnsson, B; Viktorsson, K; Wickström, M | 1 |
| Biriukova, LS; Chavynchak, RB; Rekhtina, IG; Ryzhko, VV | 1 |
| Aoyama, T; Imataki, O; Kawakami, K; Tamai, Y | 1 |
| Brand, R; Dreger, P; Michallet, M | 1 |
| Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S | 1 |
| Albo, C; Alonso, N; Arranz, R; Caballero, D; Conde, E; Fernández-Rañada, JM; Gandarillas, M; García Vela, JA; Garzón, S; Grande, C; Hernández, MT; Lahuerta, JJ; Mateos, MV; Rodríguez, J | 1 |
| Caballero, D; Canals, C; Finke, J; Goldstone, A; Hunter, A; Kienast, J; Kobbe, G; Kolb, HJ; Kyriakou, C; Metzner, B; Oberg, G; Reimer, P; Schmitz, N; Sureda, A; Theorin, N | 1 |
| Baker, N; Barker, P; Boogaerts, M; Canizo, CD; Johnsen, HE; Mesters, R; Russell, N; Schmitz, N; Schubert, J; Skacel, T | 1 |
| Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vokurka, S | 1 |
| Beske, F; Boos, J; Dantonello, T; Gadner, H; Hallmen, E; Int-Veen, C; Kazanowska, B; Klingebiel, T; Koscielniak, E; Marky, I; Treuner, J | 1 |
| Briones, J; Camós, M; Colomo, L; Escoda, L; Espinosa, I; Estany, C; Gutiérrez-García, G; López-Guillermo, A; Martínez, S; Martino, R; Mercadal, S; Montserrat, E; Pedro, C; Ribera, JM; Xicoy, B | 1 |
| Barada, WM; Bazarbachi, A; Beydoun, A; Hourani, R; Masroujeh, R; Otrock, ZK | 1 |
| Byrne, JL; Das-Gupta, EP; Devereux, S; Gonzalez, J; Haynes, AP; Ho, A; Ingram, W; McMillan, A; Mufti, GJ; Pagliuca, A; Russell, NH; Shaw, BE | 1 |
| Arkenau, T; Cunningham, D; Horwich, A; Murphy, F; Norman, A; Oates, J; Powles, R; Sirohi, B; Wotherspoon, A | 1 |
| Cheerva, AC; Gross, TG; Kadota, RP; Levine, JE; Ozkaynak, MF; Richards, MK; Rozans, MK; Sahdev, I; Shaw, PJ | 1 |
| Barbui, T; Benedetti, F; Boccadoro, M; Ciceri, F; Corradini, P; Cortelazzo, S; Gallamini, A; Gianni, AM; Magni, M; Majolino, I; Mirto, S; Passera, R; Patti, C; Pileri, A; Pizzolo, G; Rambaldi, A; Tarella, C; Zanni, M | 1 |
| Diehl, V; Evens, AM; Hutchings, M | 1 |
| Biron, P; Ghesquières, H; Labidi, SI; Nicolas, EV; Sebban, C | 1 |
| Ansell, SM; Costa, LJ; Inwards, DJ; Johnston, PB; Litzow, MR; Micallef, IN; Porrata, LF | 1 |
| Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vorkurka, S | 1 |
| Gil, L; Komarnicki, M; Kozlowska-Skrzypczak, M; Mol, A; Poplawski, D; Styczynski, J | 1 |
| Andreesen, R; Grassinger, J; Hart, C; Hennemann, B | 1 |
| Alinari, L; Baccarani, M; Derenzini, E; Fanti, S; Gandolfi, L; Musuraca, G; Stefoni, V; Tani, M; Venturini, F; Zinzani, PL | 1 |
| SEASHORE, HG | 1 |
| Bensinger, WI; Gooley, T; Gopal, AK; Holmberg, L; Maloney, D; Press, O; Zaucha, R | 1 |
| Cook, G; Crawley, C; Fields, P; Hickling, R; Hunter, A; Mahendra, P; Marcus, R; Peniket, A; Wilson, K | 1 |
| Gutweiler, JR; Kim, HB; Kozakewich, HP; Marcus, KJ; Shamberger, RC; Weldon, CB; Yu, DC | 1 |
| Brault, P; Decaudin, D; Escande, MC; Girodet, J; Mariani, P; Mathiot, C; Precupanu, CM; Zanni, M | 1 |
| Hagiwara, S; Kawabata, KC; Miwa, A; Oka, S; Tachikawa, N; Takenouchi, A; Tanimura, A; Tanuma, J | 1 |
| Benvegnú, DM; Bonfanti, G; Frediani, AV; Gonçalves, TL; Rocha, JB | 1 |
| Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M | 1 |
| Hara, T; Hatano, M; Kinoshita, Y; Koga, Y; Kohashi, K; Matsuzaki, A; Oda, Y; Saito, Y; Suminoe, A; Taguchi, T; Tajiri, T; Tsuneyoshi, M | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Pintilie, M; Seshadri, T; Tsang, R; Zadeh, S | 1 |
| Adam, Z; Bolcák, K; Cerný, J; Fakan, F; Hájek, R; Krejcí, M; Kren, L; Mayer, J; Neubauer, J; Pour, L; Smardová, L; Soumarová, R; Vanícek, J; Veselý, K | 1 |
| Batár, P; Kiss, A; Kovácsné Kovács, E; Rejto, L; Reményi, G; Sípos, T; Szarvas, M; Szász, R; Udvardy, M; Váróczy, L | 1 |
| Barreira, AA; Barros, GM; Barros, JC; Brum, DG; Burt, RK; Hamerschlak, N; Kutner, JM; Madeira, MI; Mastropietro, AP; Moraes, DA; Neto, JZ; Oliveira, EA; Oliveira, MC; Paes, AT; Pieroni, F; Porto, PP; Ribeiro, AA; Rodrigues, M; Santana, CL; Santos, AC; Simões, BP; Stracieri, AB; Tylberi, CP; Voltarelli, JC | 1 |
| Avila, DN; Bishop, MR; Bryant, KE; Danforth, DN; Fowler, DH; Gea-Banacloche, J; Gress, RE; Hardy, NM; Krumlauf, MC; Liewehr, DJ; Pavletic, S; Sportès, C; Steinberg, SM | 1 |
| Cerno, M; Damiani, D; Fanin, R; Geromin, A; Patriarca, F; Rinaldi, C; Skert, C; Sperotto, A; Stocchi, R; Tiribelli, M; Zaja, F | 1 |
| Duerst, R; Evans, L; Fouts, M; Goldman, S; Haut, P; Jacobsohn, D; Kletzel, M; Rademaker, A; Rosenfeld, A; Schaefer, C; Weinstein, J | 1 |
| Bagg, A; Carroll, M; Dierov, JK; Frey, NV; Gewirtz, AM; Goldstein, SC; Hexner, EO; Kasner, MT; Loren, AW; Luger, SM; Nasta, SD; Perl, AE; Porter, DL; Schuster, SJ; Stadtmauer, EA; Swider, CR; Tsai, DE; Vogl, DT | 1 |
| Cascavilla, N; Crescimanno, A; Di Bartolomeo, P; Di Renzo, N; Lanza, F; Marcacci, G; Musso, M; Perrone, T; Pinto, A; Scalone, R | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D | 1 |
| Kuruvilla, J | 1 |
| Qiao, W; Wang, C; Wang, T; Xing, Y; Zhao, J | 1 |
| Butler, JB; Cooke, A; Demers, A; Liu, HW; Nugent, Z; Rubinger, M; Schroeder, G; Seftel, MD; Szwajcer, D | 1 |
| Boesen, AM; Browett, P; Cunningham, D; Grigg, A; Hancock, B; Holte, H; Hoskin, P; Jack, A; Linch, DC; Maclennan, K; Qian, W; Smith, P; Trneny, M; Yung, L | 1 |
| BRAESTRUP, CB; SINGER, G; WYCKOFF, HO | 2 |
| HERSCHER, LW; WRIGHT, N | 1 |
| Ji, Z; McHale, CM; Peng, V; Ren, X; Smith, MT; Zhang, L | 1 |
| Havrdová, E; Kemlink, D; Kobylka, P; Kovárová, I; Kozák, T; Krasulová, E; Lhotáková, P; Pohlreich, D; Trneny, M; Vacková, B | 1 |
| Bakhshi, S; Malik, PS | 1 |
| Asmar, L; Beveridge, R; Boehm, KA; Mandanas, R; McGaughey, D; Orloff, G; Rifkin, R; Spitzer, G; Zhan, F | 1 |
| Schneider, AE; Talmon, GA | 1 |
| Brown, E; Hebra, A; Hudspeth, M; Jenrette, J | 1 |
| Huh, J; Kim, JE; Kim, S; Kim, SW; Lee, DH; Lee, JS; Park, CJ; Suh, C; Yoo, C | 1 |
| Behlendorf, T; Jahn, F; Jahn, P; Jordan, K; Kegel, T; Ruessel, J; Schmoll, HJ; Stein, A | 1 |
| Dong, HQ; Ji, BX; Liu, CY; Liu, YO; Su, L; Sun, WL; Wan, SG; Xu, J; Zhang, P | 1 |
| Athanasopoulos, A; Daladimos, T; Karabelis, A; Kosmas, C; Mylonakis, N; Theotikos, E; Tsakonas, G | 2 |
| Houghton, PJ; Kang, MH; Keshelava, N; Morton, CL; Reynolds, CP; Smith, MA | 1 |
| Chao, NJ; Chino, JP; Craciunescu, O; Folz, RJ; Horwitz, ME; Kelsey, CR; Marks, LB; Rizzieri, DA; Steffey, B | 1 |
| Alberghini, M; Alvegard, TA; Bacci, G; Barbieri, E; Brach Del Prever, A; Capanna, R; Carli, M; Fagioli, F; Ferrari, S; Gandola, L; Luksch, R; Mapelli, S; Mercuri, M; Picci, P; Prete, A; Smeland, S; Sundby Hall, K; Tamburini, A; Tienghi, A; Wiebe, T | 1 |
| Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH | 1 |
| Castellano, A; De Ioris, MA; De Pasquale, MD; De Vito, R; Donfrancesco, A; Garganese, MC; Ilari, I; Inserra, A; Jenkner, A; Locatelli, F; Natali, G; Ravà, L | 1 |
| Hadjidaniel, MD; Reynolds, CP | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Glimelius, B; Lahn, M | 1 |
| al-Farsi, K; Crump, M; Franke, N; Keating, A; Kuruvilla, J; Pintilie, M; Puig, N; Seshadri, T | 1 |
| Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J | 1 |
| Ashley, DM; Bandopadhayay, P; Cohn, RJ; Downie, PA; Hassall, TE; Kirby, ML; Rosenfeld, JV; Sullivan, MJ; Wheeler, GC | 1 |
| Bockova, J; Brandejsova, R; Bystricka, E; Chvojkova, I; Mazur, E; Mjartanova, D; Scudlova, J; Streinerova, K; Vasilieva, E; Visokaiova, M; Vitkova, J; Vodickova, M; Vokurka, S; Vrabcova, M | 1 |
| Cai, JL; Delioukina, M; Forman, SJ; Gaal, K; Kogut, N; Nademanee, A; Palmer, JM; Popplewell, L; Tsai, NC | 1 |
| Glass, B; Griesinger, F; Hasenkamp, J; Hohloch, K; Lakhani, VJ; Meller, J; Riggert, J; Sahlmann, CO; Trümper, L; Wulf, G | 1 |
| Ashizawa, M; Kako, S; Kanda, Y; Kikuchi, M; Kimura, S; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sakamoto, K; Sato, M; Terasako, K; Wada, H; Yamazaki, R | 1 |
| Castillo, L; Chantada, GL; Diez, B; Dufort, G; Koop, K; Palma, J; Richard, L; Sampor, C; Sasso, DF | 1 |
| Boos, J; Hempel, G; Kersting, G; Lippert, J; Willmann, S; Würthwein, G | 1 |
| Caballero, MD; Capria, S; Cuberli, F; Falcioni, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Giardini, C; Gobbi, M; Isidori, A; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Sarina, B; Specchia, G; Stefani, PM; Visani, G | 1 |
| Bartlett, NL; Cashen, AF; Foyil, KV; Grove, LE; Kennedy, DA | 1 |
| Shigematsu, A | 1 |
| Balogh, A; Duan, Q; Duggan, P; Russell, J; Shafey, M; Stewart, DA | 1 |
| Dib, M; Gagnadoux, F; Paris, A; Rousselet, MC; Tazi, A; Urban, T | 1 |
| Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A | 1 |
| Barzał, J; Gawroński, K; Młot, B; Oborska, S; Rzepecki, P; Szczylik, C; Waśko-Grabowska, A | 1 |
| Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Massey, C; Puig, N; Seshadri, T; Tsang, R; Villa, D | 1 |
| de Rooij, M; Huijgens, PC; Visser, OJ; Wondergem, MJ; Zijlstra, JM; Zweegman, S | 1 |
| Avigdor, A; Avivi, I; Levi, I; Nagler, A; Or, R; Patachenko, P; Rowe, JM; Shimoni, A; Yeshurun, M; Zwas, T | 1 |
| Briere, J; Bron, D; Cogliatti, S; Cuccuini, W; Gaulard, P; Gisselbrecht, C; Hirchaud, E; Houlgatte, R; Mounier, N; Rosenwald, A; Soulier, J; Sundstrom, C; Thieblemont, C; Voelker, HU; Ysebaert, L | 1 |
| Ardeshna, K; Kayani, I; Linch, DC; Lowry, L; Moore, S; Peggs, K; Qian, W; Thomson, K | 1 |
| Dehghani, M; Haghighinejad, H; Mohamadian, M; Nourani, H; Ramzi, M; Vojdani, R; Zakerinia, M | 1 |
| Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L | 1 |
| Ma, X; Ren, C; Sheng, Z; Wang, B; Xia, B; Zhang, W | 1 |
| Atchaneeyasakul, LO; Buaboonnam, J; Chiewvit, P; Sanpakit, K; Trinavarat, A | 1 |
| Aznar Oroval, E; García-Lozano, T; Juan Bañón, JL; Lorente Alegre, P | 1 |
| Andersen, NS; Bentzen, H; Brown, P; Delabie, J; Ehinger, M; Elonen, E; Eriksson, M; Geisler, CH; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kuittinen, O; Laurell, A; Lauritzsen, GF; Nilsson-Ehle, H; Nordström, M; Pedersen, LB; Ralfkiaer, E; Räty, R; Sundström, C | 1 |
| Bianciotto, CG; Iturralde, JC; Kaliki, S; Rojanaporn, D; Say, EA; Shields, CL | 1 |
| Abate, ME; Barbieri, E; Bisogno, G; Daolio, P; Eriksson, M; Fagioli, F; Ferrari, S; Gandola, L; Grignani, G; Hall, KS; Lindholm, P; Luksch, R; Picci, P; Podda, M; Prete, A; Ruggieri, P; Smeland, S; Tamburini, A; Tienghi, A | 1 |
| Beuthien-Baumann, B; Bornhäuser, M; Ehninger, G; Kroschinsky, F; Middeke, JM; Ordemann, R; Platzbecker, U; Platzek, I; Stöhlmacher, J; van den Hoff, J; Zietz, C | 1 |
| Ceciliano, A; Chantada, GL; Dominguez, J; Fandino, AC; Millan, N; Schaiquevich, P; Taich, P; Villasante, F | 1 |
| Cooney, JP; Kruger, PC; Turner, JH | 1 |
| Anderson, D; Greaves, P; Gribben, JG; Lillington, D; Lister, TA; Matthews, J; Montoto, S | 1 |
| Atalla, A; Borges dos Santos, K; Hallack Neto, AE | 1 |
| Fukayama, M; Kurokawa, M; Nakamura, F; Takazawa, Y; Uni, M; Yoshimi, A | 1 |
| Boldrini, R; Castellano, A; Contoli, B; Corneli, T; Crocoli, A; DE Ioris, MA; DE Pasquale, MD; DE Sio, L; Garganese, MC; Jenkner, A; Pessolano, R; Serra, A | 1 |
| Joung, YS; Kim, JH; Koo, HH; Lee, SH; Lim, DH; Shin, HJ; Son, MH; Suh, YL; Sung, KW; Yoo, KH | 1 |
| Mendonça-Torres, MC; Roberts, SS | 1 |
| Ambinder, R; Ayala, E; Burns, LJ; Carter, S; Fenske, T; Fisher, R; Horowitz, M; Mineshi, S; Moskowitz, CH; Press, OW; Stadtmauer, EA; Tomblyn, M; Vose, JM | 1 |
| Berdel, WE; Demant, A; Evers, G; Kessler, T; Köhler, G; Krug, U; Kuhlmann, M; Mesters, R; Mikesch, JH; Mohr, M; Müller-Tidow, C; Pohlen, M; Schliemann, C; Schmidt, E; Thoennissen, GB; Thoennissen, NH; Wessling, J | 1 |
| Fortney, J; Gencheva, M; Gibson, LF; Hare, I; Kurian, S; Piktel, D; Wysolmerski, R | 1 |
| Aslan, D; Cetin, M; Eroglu, C; Eser, B; Kaynar, L; Keklik, M; Kurnaz, F; Mentes, S; Orhan, O; Sahin, C; Sivgin, S; Soyuer, S; Unal, A; Yildiz, OG | 1 |
| Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E | 1 |
| Ara, T; Buettner, R; DeClerck, YA; Groshen, SG; Ji, L; Jove, R; Nakata, R; Seeger, RC; Sheard, MA; Shimada, H; Yu, H | 1 |
| Du, J; Fan, JL; Fu, WJ; Hou, J; Jiang, H; Jin, LN; Li, R; Xi, H; Zeng, TM; Zhang, CY; Zhou, LL | 1 |
| Bembnista, E; Czyz, A; Dytfeld, D; Gil, L; Kazmierczak, M; Komarnicki, M; Kozlowska-Skrzypczak, M; Lojko-Dankowska, A; Matuszak, M; Nowicki, A | 1 |
| Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; Whalen, V; William, BM | 1 |
| Baek, HJ; Han, JW; Im, HJ; Kang, HJ; Koh, KN; Lee, SH; Park, HJ; Park, KD; Sung, KW | 1 |
| Czajczynska, A; Gramatzki, M; Günther, A; Humpe, A; Kneba, M; Nickelsen, M; Raff, T; Repp, R; Schrappe, M; Schrauder, A; Schub, N | 1 |
| Blijlevens, NM; de Haan, AF; Donnelly, JP; Herbers, AH; van der Velden, WJ | 1 |
| Go, A; Guo, R; Parthasarathy, M; Rodriguez, T; Smith, S; Sobol, U; Stiff, P; Vimr, R | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Calandrelli, M; Capelli, D; Chiarucci, M; Gini, G; Inglese, E; Leoni, P; Mancini, G; Mancini, S; Montanari, M; Offidani, M; Olivieri, A; Poloni, A; Raggetti, G; Scortechini, I | 1 |
| Abate, ME; Balladelli, A; Cesari, M; Fagioli, F; Ferrari, S; Luksch, R; Marchesi, E; Paioli, A; Palmerini, E; Pratelli, L; Tamburini, A | 1 |
| Chung, JS; Kim, H; Kim, JS; Lee, GW; Lee, HS; Lee, WS; Shin, HJ; Song, MK; Yhim, HY | 1 |
| Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM | 1 |
| Ardeshna, KM; Bird, A; Goldstone, AH; Kothari, J; Lambert, J; Linch, DC; Morris, E; Peggs, KS; Thomson, KJ; Virchis, AE | 1 |
| Bubalo, J; Carpenter, PA; Leather, HL; Majhail, N; Marks, DI; Perales, MA; Pidala, J; Savani, BN; Shaughnessy, P; Wingard, J | 1 |
| Chihara, D; Chou, T; Hasegawa, Y; Henzan, H; Izutsu, K; Kaneko, H; Kato, K; Kondo, E; Mizuta, S; Sakai, R; Sakamaki, H; Sugahara, H; Suzuki, R; Suzumiya, J; Yokoyama, K | 1 |
| Buck, A; Duell, J; Einsele, H; Knop, S; Maeder, U; Rasche, L; Rosenwald, A; Strifler, S | 1 |
| CHARTERIS, AA | 1 |
| BATHO, HF; EVANS, AM; MIBUS, SA; MOFFAT, RG; NASH, RD | 1 |
| Belada, D; Berková, A; Bolomská, I; Burešová, L; Campr, V; Klener, P; Kozák, T; Kubáčková, K; Matuška, M; Pirnos, J; Přibylová, J; Pytlík, R; Sýkorová, A; Trněný, M; Vášová, I | 1 |
| Bentzen, H; Bogsrud, TV; Brown, Pde N; Delabie, J; Ehinger, M; Elonen, E; Fagerli, UM; Frederiksen, H; Geisler, CH; Grønbæk, K; Hansen, PB; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kostova-Aherdan, K; Laurell, A; Lauritzsen, GF; Lehmann, AK; Loft, A; Nilsson-Ehle, H; Pedersen, LB; Ralfkiaer, E; Räty, R; Schildt, J; Sundstrom, C | 1 |
| Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY | 1 |
| Auger-Quittet, S; Daures, JP; Duny, Y; Quittet, P | 1 |
| Daw, S; Hayward, J; Hewitt, M; Kirkwood, A; McCarthy, K; Morland, B; Shankar, A | 1 |
| Behfar, M; Beiki, D; Eftekhari, M; Fallahi, B; Fard-Esfahani, A; Ghavamzadeh, A; Hamidieh, AA; Hosseini, AS; Paragomi, P; Shamshiri, A | 1 |
| Caballero, MD; Cabrero-Calvo, M; García-Sanz, R; Labrador, J; Mateos, MV; Pérez-López, E; Vázquez, L | 1 |
| Atalla, A; Costa, LJ; dos Santos, KB; Hallack-Neto, AE; Pereira, J | 1 |
| D'Sa, S; Dorman, J; Marzolini, MA; Thomson, KJ | 1 |
| Imai, K; Kato, T; Miyao, K; Niimi, K; Ono, Y; Sakai, T; Sakemura, R; Sawa, M; Tsushita, N | 1 |
| Bailly, C; Bal-Mahieu, C; Boulet, E; Guilbaud, N; Kruczynski, A; Lansiaux, A; Lartigau, E; Leblond, P; Meignan, S; Pillon, A; Sarrazin, T | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Arranz, R; Bargay, J; Bello, JL; Caballero, MD; Conde, E; Coronado, M; González-Barca, E; Grande, C; Hernández, MT; Marín-Niebla, A; Martín, A; Montes-Moreno, S; Panizo, C; Pardal, E; Pérez-Ceballos, E | 1 |
| Choi, YB; Koo, HH; Lee, NH; Lee, SH; Lim, DH; Shin, HJ; Son, MH; Sung, KW; Yoo, KH | 1 |
| Bates, A; Cooke, R; Cunningham, D; Falk, SJ; Gilson, D; Hancock, BW; Harris, SJ; Horwich, A; Hoskin, PJ; Linch, DC; Lister, A; Lucraft, HH; Radford, J; Stevens, AM; Swerdlow, AJ; Syndikus, I; Williams, MV | 1 |
| Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Nagai, H | 1 |
| Beck, JF; Ebinger, M; Feuchtinger, T; Furtwängler, R; Greil, J; Handgretinger, R; Illhardt, T; Klingebiel, T; Lang, P; Schlegel, PG; Schwarze, CP | 1 |
| Banat, A; Basara, N; Derigs, G; Flohr, T; Frickhofen, N; Gramatzki, M; Hess, G; Kirschey, S; Kolbe, K; Link, H; Meyer, RG; Peter, N; Schmitz, N; Schulz, A; Theobald, M; Weidmann, E; Wolf, HH | 1 |
| Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A | 1 |
| Akpek, G; Aljurf, M; Artz, A; Bredeson, CN; Chen, YB; Cooke, KR; Ho, VT; Lane, AA; Lazarus, HM; Logan, B; McCarthy, P; Olsson, R; Pasquini, MC; Saber, W; Zhu, X | 1 |
| Asada, H; Fujino, Y; Goto-Koshino, Y; Ohno, K; Tomiyasu, H; Tsujimoto, H | 1 |
| Bersonda, J; Ji, Z; McHale, CM; Smith, MT; Tung, J; Zhang, L | 1 |
| Ford, PA; Grant, SJ; Keck, G; Mick, R | 1 |
| Caimi, PF; Campagnaro, EL; Cooper, BW; Creger, RJ; de Lima, M; Fox, R; Fu, P; Gerson, SL; Lazarus, HM; Reese-Koc, J; Silva Rondon, CH; William, BM | 1 |
| Ahn, HS; Hong, CR; Ju, HY; Kang, HJ; Kim, H; Kim, HS; Kim, MS; Lee, JW; Park, JD; Park, KD; Park, SH; Shin, HY | 1 |
| Fukuoka, K; Kuji, I; Matsutani, M; Nishikawa, R; Suzuki, T; Watanabe, Y; Yanagisawa, T | 1 |
| Abidi, MH; Ayash, L; Bhutani, D; Deol, A; Dyson, G; Jain, T; Kim, S; Lum, LG; Ratanatharathorn, V; Uberti, JP; Veeraputhiran, M | 1 |
| Kawaguchi, H; Kobayashi, M; Kurisu, K; Nosaka, R; Sugiyama, K; Takayasu, T; Yamasaki, F | 1 |
| Ben-Haroush, A; Even-Or, E; Stein, J; Yahel, A; Yaniv, I | 1 |
| Altuntaş, F; Civriz Bozdağ, S; Durgun, G; Esbah, O; Kaya, A; Kayıkçı, Ö; Kocubaba, Ş; Şirinoğlu Demiriz, I; Tekgündüz, E; Tetik, A | 1 |
| Bachy, E; Casasnovas, O; Freyer, G; Guitton, J; Hénin, E; Ribrag, V; Salles, G; Sebban, C; Tilly, H; Tod, M; You, B | 1 |
| Golubeva, OV; Gorovtsova, OV; Gorshkov, IM; Krivovyaz, OS; Polyakov, VG; Ushakova, TL; Yarovoy, AA | 1 |
| Bonizzoni, E; Carella, AM; Cascavilla, N; Ciochetto, C; Crescimanno, A; Di Carlo, P; Di Nicola, M; Di Renzo, N; Donnarumma, D; Lanza, F; Marcacci, G; Matera, R; Mele, A; Merenda, A; Messina, G; Moscato, T; Musso, M; Orciuolo, E; Pastore, D; Pavone, V; Pinto, A; Santarone, S; Scalone, R; Scalzulli, PR; Vitolo, U | 1 |
| Elborai, Y; Elhaddad, A; Hafez, H; Hammad, M; Hussein, H; Lehmann, L; Moussa, EA | 1 |
| Angrilli, F; Baldini, L; Cascavilla, N; Federico, M; Ferrari, A; Galimberti, S; Gobbi, PG; Ilariucci, F; Luminari, S; Mammi, C; Marcheselli, L; Merli, F; Musso, M; Polimeno, G; Scalzulli, PR; Stelitano, C | 1 |
| Gore, A; Gupta, A; Jain, R; Jeevangi, N; Kannan, S; Khattry, N; Nair, R; Saikia, T; Thippeswamy, R | 1 |
| Aplenc, R; Bagatell, R; Desai, AV; Fisher, BT; Getz, K; Huang, V; Li, Y; Mante, A; Seif, AE | 1 |
| Bojic, M; Greinix, H; Hermann, A; Jäger, U; Kalhs, P; Lamm, W; Leiner, M; Mitterbauer, M; Rabitsch, W; Schörgenhofer, C; Schulenburg, A; Sillaber, C; Skrabs, K; Sperr, WR; Wohlfarth, P | 1 |
| Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF | 1 |
| Boulahdour, H; Daguindau, E; Deconinck, E; Helias, P; Philippe, L; Puyraveau, M | 1 |
| Buzzonetti, L; Cozza, R; De Ioris, MA; Natali, G; Romanzo, A; Valente, P | 1 |
| Bagatell, R; Bunin, NJ; Desai, AV; Grupp, SA; Heneghan, MB; Li, Y; Seif, AE | 1 |
| Ardeshna, KM; Foley, M; Kothari, J; Lambert, J; Linch, DC; Mackenzie, S; Morris, E; Peggs, KS; Thomson, K; Virchis, AE | 1 |
| Ashizawa, M; Fujiwara, S; Hatano, K; Ito, S; Kako, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Okazuka, K; Sato, K; Sugimoto, M; Suzuki, T; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Abboud, C; Cashen, AF; Ceriotti, C; DiPersio, J; Fletcher, T; Gao, F; Ghobadi, A; Stockerl-Goldstein, K; Vij, R | 1 |
| Evans, R; Fortney, J; Gibson, LF; Hare, I; Moses, B; Piktel, D; Slone, W | 1 |
| Beck-Popovic, M; Bergin, C; Gaillard, MC; Houghton, S; Mosimann, P; Munier, FL; Puccinelli, F; Stathopoulos, C | 1 |
| Bhat, V; Khattry, N; Toshniwal, M; Vira, H | 1 |
| Butcher, B; Chong, G; Cull, G; Fay, K; Filshie, R; Gandhi, MK; Gill, D; Grigg, A; Hahn, U; Hertzberg, M; Hicks, RJ; Ho, SJ; Hofman, MS; Johnston, A; Kannourakis, G; Lewis, ID; Milliken, S; Renwick, W; Seymour, JF; Taper, J; Trotman, J; Warburton, P; Watson, AM; Wirth, A | 1 |
| Cho, EJ; Cho, HW; Koo, HH; Lee, JW; Lee, S; Lee, SK; Lim, DH; Ma, Y; Sung, KW; Yoo, KH | 1 |
| Amorim, S; Bachy, E; Bay, JO; Bento, L; Bonifazi, F; Bouabdallah, R; Boumendil, A; Ceballos, P; Crawley, C; Damaj, G; Dreger, P; Finel, H; Gribben, J; Guilhot, F; Haenel, A; Huynh, A; Johnson, R; Le Gouill, S; Malladi, R; McQuaker, G; Metzner, B; Monjanel, H; Montoto, S; Nicolas-Virelizier, E; Orchard, K; Pohlreich, D; Poiré, X; Rambaldi, A; Rossi, G; Russell, NH; Thomson, K; Tilly, H | 1 |
| Bechtold, M; Berry, JL; Jubran, R; Kim, JW; Reid, M; Shah, S; Zolfaghari, E | 1 |
| Daugel-Dauge, NO; Durnev, AD; Kulakova, AV; Pligina, KL; Zhanataev, AK | 1 |
| Cassaday, RD; Cowan, A; Ermoian, R; Gopal, AK; Graf, SA; Holmberg, LA; Press, OW; Shadman, M; Smith, SD; Stevenson, PA; Till, BG; Tseng, YD | 1 |
| Fujii, T; Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Iwadate, D; Kawada, M; Ohashi, K; Sawa, N; Sekine, A; Sumida, K; Suwabe, T; Takaichi, K; Ubara, Y; Wake, A; Yamanouchi, M; Yuasa, M | 1 |
| Alenxandrova, K; Arfi-Rouche, J; Bourhis, JH; Castilla-Llorente, C; Danu, A; Ghez, D; Khalife-Saleh, N; Koscielny, S; Lapierre, V; Lazarovici, J; Legoupil, C; Michot, JM; Pilorge, S; Ribrag, V; Saleh, K | 1 |
| Bruno, B; Chalandon, Y; Charbonnier, A; Coiteux, V; Simon, N; Souchet, L; Taque, S; Vincent, L; Yakoub-Agha, I | 1 |
| Lavolé, J; Le Goff, M; Mallet, V; Oudjit, A; Sogni, P | 1 |
| Braziel, RM; Chansky, K; Chen, AI; Dunlap, JB; Fan, G; Gay, ND; Leonard, JT; Maziarz, RT; Okada, CY; Raess, PW; Stentz, A | 1 |
| Baars, JW; Brouwer, R; Chamuleau, MED; de Jong, D; de Wreede, LC; Demandt, AMP; Doorduijn, JK; Hardi, L; Kersten, MJ; Kluin, PM; Nijland, M; Oosten, LEM; Siemes, C; Smeekes, OS; Stevens, WBC; Thielen, FW; Uyl-de Groot, CA; van Imhoff, GW; Veelken, H | 1 |
| Ansuinelli, M; Canfora, M; Cantonetti, M; Capria, S; Caputo, MD; Di Rocco, A; Giannarelli, D; Gumenyuk, S; Marchesi, F; Mengarelli, A; Palombi, F; Papa, E; Pisani, F; Provenzano, I; Pupo, L; Renzi, D; Romano, A; Serrao, A; Spadea, A; Trisolini, SM | 1 |
| Akhtar, S; Elhassan, TAM; Elshenawy, MA; Maghfoor, I; Shahzad Rauf, M | 1 |
| Avni, B; Grisariu, S; Or, R; Shapira, MY | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Ma, J; Milgrom, S; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Timmons, M; Valdez, BC | 1 |
| Fornecker, LM; Guffroy, A; Korganow, AS; Martin, M; Meyer, A | 1 |
| Dandoy, CE; Davies, SM; Jodele, S; Lane, A; Myers, K; Teusink-Cross, A; Wallace, G; Weiss, B | 1 |
| Asanuma, H; Shima, H; Shimada, H; Yamada, Y | 1 |
| Fukushima, T; Hara, J; Hishiki, T; Ikeda, H; Kamijo, T; Kaneko, M; Kaneko, T; Kuroda, T; Matsumoto, K; Nakagawara, A; Nakazawa, A; Ohira, M; Shichino, H; Soejima, T; Tajiri, T; Takahashi, H; Takimoto, T; Teramukai, S; Yokota, I; Yoneda, A | 1 |
| Boehm, A; Keil, F; Koller, E; Menschel, E; Moestl, M; Noesslinger, T; Panny, M; Simanek, R | 1 |
| Billio, A; Borghero, C; Calimeri, T; Carli, G; Cascavilla, N; Centurioni, R; Chiusolo, P; Codeluppi, K; Fama, A; Fanin, R; Federici, I; Ferrero, S; Finotto, S; Gherlinzoni, F; Ghione, P; Giannoccaro, M; Lanza, F; Loseto, G; Marino, D; Matera, R; Mazzone, AM; Mosna, F; Olivieri, A; Olivieri, J; Orciuolo, E; Pelosini, M; Perali, G; Rattotti, S; Saraceni, F; Sgherza, N; Sica, S; Stefani, PM; Tisi, MC; Tomei, G; Zaja, F | 1 |
| Ando, K; Fukuhara, N; Gomyo, H; Hanamura, I; Hotta, T; Kobayashi, H; Kobayashi, N; Kumagai, K; Kurosawa, M; Maruyama, D; Matsuno, Y; Miyazaki, K; Morishima, Y; Nagai, H; Nakamura, S; Nosaka, K; Ogura, M; Ohmachi, K; Ohnishi, K; Ohyashiki, K; Sawada, K; Shimoyama, T; Takayama, N; Taniwaki, M; Tobinai, K; Tsukamoto, N; Tsukasaki, K; Uike, N; Usuki, K; Utsumi, T; Wakabayashi, M; Yakushijin, Y; Yamamoto, K | 1 |
| Aplenc, R; Bagatell, R; Desai, AV; Fisher, B; Getz, K; Huang, V; Li, Y; Seif, AE | 1 |
| Abou Mourad, Y; Clissa, C; Connors, JM; Gerrie, AS; Guiducci, B; Isidori, A; Loscocco, F; Nantel, SH; Power, M; Sanford, D; Savage, KJ; Scott, DW; Sehn, LH; Song, K; Sutherland, H; Toze, C; Tsang, ES; Villa, D; Visani, G | 1 |
| Baker, KS; Carpenter, PA; El-Haddad, A; Elzembely, MM; Park, JR; Pinto, N; Riad, KF; Sayed, HA | 1 |
| Boddy, AV; Duong, JK; Errington, J; Ladenstein, R; Nath, CE; Shaw, PJ; Veal, GJ | 1 |
| Barnett, MH; Barnett, Y; Ford, CD; Hendrawan, K; Khoo, ML; Kyle, KA; Ma, DDF; Ma, KC; Massey, JC; Milliken, ST; Moore, JJ; Sutton, IJ; Zaunders, JJ; Zivadinov, R | 1 |
| Bando-Polaino, I; Cabezas-Camarero, S; de la Orden García, V; Díaz-Rubio, E; García-Barberán, V; Llovet García, P; Mediero-Valeros, B; Merino Menéndez, S; Pérez-Segura, P; Subhi-Issa, AI | 1 |
| Chen, J; Huang, H; Jiang, Y; Jin, Z; Liu, S; Ruan, J; Wu, D; Xiao, X; Zhang, L; Zhang, X | 1 |
| Abounader, D; Andritsos, L; Benson, DM; Bolwell, B; Dean, R; Devine, SM; Efebera, YA; Elder, P; Hill, B; Hofmeister, CC; Jagadeesh, D; Jaglowski, S; Kalaycio, M; Majhail, NS; Penza, S; Pohlman, B; Rosko, A; Sharma, N; Singer, S; Sobecks, R; Vasu, S; William, BM; Zhao, Q | 1 |
| Bishton, M; Campbell, R; Cheah, CY; Cochrane, T; De Mel Widanalage, S; Gilbertson, M; Hapgood, G; Hawkes, E; Hill, K; Johnston, A; Lee, HP; Manos, K; Nelson, N; Ng, M; Ng, ZY; Opat, S; Poon, M; Purtill, D; Ratnasingam, S; Ritchie, D; Schwarer, A; Seymour, J; Shorten, S; Sunny, T; Tam, C; Xin, L | 1 |
| Cheon, JE; Choi, JY; Choi, YH; Hong, CR; Hong, KT; Kang, HJ; Kim, IH; Kim, SK; Lee, YJ; Park, JD; Park, KD; Park, SH; Phi, JH; Shin, HY; Wang, KC | 1 |
| Hara, J; Okada, K; Sakamoto, H; Soejima, T; Yamasaki, K | 1 |
| Hagiwara, S; Nagai, H; Okada, S; Saito, AM; Uehira, T | 1 |
| Barlogie, B; Mouhieddine, TH; Teruya-Feldstein, J | 1 |
| Arora, R; Hildebrandt, GC; Munker, R; Qasrawi, A; Ramlal, R | 1 |
| Abraham, J; Borel, C; Bouabdallah, K; Bouabdallah, R; Casasnovas, RO; Chantepie, S; Damaj, G; Delapierre, B; Delette, C; Durot, E; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Gyan, E; Houot, R; Hueso, T; Ibrahim, A; Le Gouill, S; Lemal, R; Malak, S; Morello, R; Peyrade, F; Tchernonog, E; Tessoulin, B; Tournilhac, O | 1 |
| Ahmed, S; Ahn, KW; Aljurf, M; Bacher, U; Badawy, SM; Bejanyan, N; Cairo, M; Cerny, J; Epperla, N; Farhadfar, N; Fenske, TS; Freytes, CO; Gale, RP; Hamadani, M; Haverkos, B; He, Y; Hossain, N; Inwards, D; Jagadeesh, D; Kamble, RT; Kenkre, VP; Kharfan-Dabaja, MA; Lazarus, HM; Lazaryan, A; Lekakis, L; Litovich, C; Majhail, NS; Mei, M; Murthy, HS; Mussetti, A; Nathan, S; Nishihori, T; Olsson, RF; Ramakrishnan Geethakumari, P; Savani, BN; Sureda, A; Yared, JA | 1 |
| Chen, Q; Dong, Y; Mo, X; Xia, J; Zhang, B; Zhang, J; Zhang, L; Zhang, S | 1 |
| Böhmer, LH; Chitu, DA; de Jong, D; de Jongh, E; de Weerdt, O; Doorduijn, JK; Hoogendoorn, M; Kersten, MJ; Kibbelaar, RE; Kluin-Nelemans, HC; Leys, RBL; Lugtenburg, PJ; MacKenzie, MA; Minnema, MC; Snijders, TJF; van Gelder, M; van Marwijk Kooij, R; Van't Veer, MB; Zijlstra, JM | 1 |
| Eich, HT; Scobioala, S | 1 |
| Bae, SH; Choi, Y; Jo, JC; Kim, IH; Kim, JS; Lee, JH; Lee, SM; Lee, WS; Lee, YJ; Lim, SN; Yoon, SS | 1 |
| Ballotta, L; Capria, S; Celentano, M; Ferrara, F; Marchesi, F; Mengarelli, A; Papa, E; Pedata, M; Picardi, A; Regazzo, G; Riccardi, C; Riemma, C; Terrenato, I; Trisolini, S | 1 |
| Arakawa, Y; Hiwatari, M; Hogetsu, K; Kato, S; Koh, K; Kubota, Y; Takita, J; Watanabe, K | 1 |
| Adachi, S; Hiramatsu, H; Horikoshi, Y; Kato, I; Kawaguchi, K; Ogura, T; Saida, S; Takachi, T; Takita, J; Umeda, K; Watanabe, K | 1 |
| Kelsey, P; Kirkland, K; Lambert, J; Malladi, R; Morley, N; Paul, R; Pearce, R; Peniket, A; Perry, J; Snowden, JA | 1 |
| Allione, B; Calimeri, T; Cattaneo, C; Donadoni, G; Facchetti, F; Ferrari, D; Ferreri, AJM; Foppoli, M; Fumagalli, L; Lleshi, A; Pecciarini, L; Ponzoni, M; Re, A; Rigacci, L; Rossi, G; Sassone, M; Spina, M; Verga, L | 1 |
| Cartron, G; Casasnovas, O; Dalban, C; Ghesquières, H; Hernandez, C; Jardin, F; Le Bras, F; Le Gouill, S; Metzger, S; Nicolas-Virelizier, E; Pérol, D; Vizoso, S | 1 |
| Akkurt, DM; Cinli, TA; Demir, I; Durusoy, SS; Gunes, AK; Ince, I; Ozkan, G; Pehlivan, M; Sarifakiogullari, S; Serin, I | 1 |
| Boudreault, JS; Desjardins, A; Feng, X; Le-Nguyen, V; Rioux, JP; Turgeon-Mallette, L; Veilleux, A; Vo, C | 1 |
| Birkmann, J; Blaudszun, AR; Bornhäuser, M; Ehninger, G; Fiedler, F; Fricke, S; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Kürzel, S; Schaefer-Eckart, K; Stahl, L | 1 |
| Bosch, M; Danyluk, P; Dusyk, T; Elemary, M; Hahn, L; Lim, H; Sabry, W; Stakiw, J | 1 |
| Ashkenazi, M; Avni, B; Grisariu, S; Lebel, E; Stepensky, P; Vainstein, V; Zimran, E | 1 |
| Bouabdallah, K; Casasnovas, RO; Costes-Tertrais, D; Damaj, G; Dartigeas, C; Delette, C; Fogarty, P; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Houot, R; Hueso, T; Le Gouill, S; Malak, S; Oberic, L; Ribrag, V; Tchernonog, E; Thieblemont, C | 1 |
| An, LC; Chen, LM; Chu, XX; Feng, XY; Li, KM; Liu, XQ; Liu, YH; Ma, JJ; Sui, JR; Wang, JY; Wei, RX; Xu, JQ | 1 |
| Do, YR; Kang, HJ; Kim, HG; Kim, KH; Kim, WS; Kong, JH; Kwak, JY; Lee, JH; Lee, M; Mun, YC; Oh, SY; Park, MR; Park, SK; Park, Y; Shin, HJ; Won, JH; Yang, DH | 1 |
| Chen, X; Chu, J; Huang, H; Jiang, Y; Jin, Z; Li, C; Liu, S; Qian, C; Qu, C; Wu, D; Xu, T; Yang, H; Zhang, L; Zhang, X; Zhou, J; Zhu, Q | 1 |
| Bojalil-Alvarez, L; Fernández-Gutiérrez, JA; Garcia-Villasenor, E; Gomez-Almaguer, D; Gómez-Gomez, ET; Gutierrez-Aguirre, CH; Karduss-Urueta, AJ; Litzow, MR; Murrieta-Alvarez, I; Reyes-Cisneros, OA; Ruiz-Arguelles, GJ; Ruiz-Delgado, GJ | 1 |
| Bauer, S; Baumhoer, D; Bernkopf, M; Bhadri, V; Bonar, F; Bovee, J; Brichard, B; Burdach, S; Butterfaß-Bahloul, T; Collaud, S; Cyprova, S; Dhooge, C; Dirksen, U; Egerer, G; Eich, HT; Ek, T; Faldum, A; Gelderblom, H; Hardes, J; Hartmann, W; Hassenpflug, W; Hauser, P; Haveman, L; Hjorth, L; Hong, A; Jürgens, H; Kanerva, J; Kessler, T; Kiss, J; Koch, R; Kruseova, J; Kühne, T; Metzler, M; Paulussen, M; Raciborska, A; Ranft, A; Rascon, J; Reichardt, P; Renard, M; Timmermann, B; van den Berg, H; Vieth, V | 1 |
| Bashey, A; Brown, S; Holland, HK; Jackson, KC; Morris, LE; Shegda, N; Solh, M; Solomon, SR; Zhang, X | 1 |
| Chen, JB; Liu, L; Tang, XQ; Wang, J; Wang, L; Wang, X; Xiong, YY; Zhang, HB | 1 |
| Ghraichy, M; Jelcic, I; Martin, R; Müller, AM; Ruder, J; Schanz, U; Trück, J; von Niederhäusern, V | 1 |
| Chari, A; Cho, HJ; Jakubowski, R; Moshier, E; Mouhieddine, TH; Parekh, S; Puliafito, B; Rattu, M; Richard, S; Richter, J; Rodriguez, C; Rossi, A; Sanchez, L; Steinberg, A; Thibaud, S | 1 |
| Brennan, B; Fenwick, N; Gaspar, N; Gelderblom, H; Kirton, L; Laurence, V; Marec-Bérard, P; Martín-Broto, J; Moroz, V; Owens, C; Sastre, A; Strauss, S; Wheatley, K; Whelan, J | 1 |
| Avni, B; Cohen, YI; Grisariu, S; Lebel, E; Shaulov, A; Stepensky, P; Zimran, E | 1 |
| Arcese, W; Ciceri, F; Gedde-Dahl, T; Gorin, NC; Labopin, M; Lanza, F; Maertens, J; Meijer, E; Mohty, M; Montoro, J; Pabst, T; Pérez-Simón, JA; Sanz, J; Schaap, N; Van Gorkom, G; Versluis, J; Vrhovac, R | 1 |
41 review(s) available for etoposide and melphalan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches.
Topics: Animals; Biocatalysis; Chemistry, Pharmaceutical; DNA Topoisomerases, Type II; Drug Discovery; Humans; Topoisomerase II Inhibitors | 2018 |
Hypersensitivity reactions.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomycin; Chlorambucil; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Drug Hypersensitivity; Etoposide; Fluorouracil; Humans; Ifosfamide; Melphalan; Methotrexate; Mitomycins; Neoplasms; Paclitaxel; Pentostatin; Procarbazine; Teniposide | 1992 |
Conditioning regimens for allogeneic bone marrow transplantation.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia; Lymphocyte Depletion; Melphalan; T-Lymphocytes; Transplantation, Homologous; Whole-Body Irradiation | 1992 |
Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Mitomycin; Mitoxantrone; Neoplasm Metastasis; Vincristine | 1992 |
[Treatment of relapses and failures in disseminated Hodgkin's disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Epirubicin; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Mechlorethamine; Melphalan; Methotrexate; Mitoguazone; Prednisone; Procarbazine; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine | 1991 |
What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin's disease?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Drug Resistance; Etoposide; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Melphalan; Neutropenia; Pilot Projects; Randomized Controlled Trials as Topic; Registries; Time Factors; Transplantation, Autologous | 1991 |
[Use of recombinant hematopoietic growth factors after chemotherapy and high-dose chemo-radiotherapy].
Topics: Anemia, Aplastic; Antineoplastic Agents; Colony-Stimulating Factors; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Neoplasms; Radiotherapy | 1989 |
Etoposide: fifteen years experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Lomustine; Melphalan; Mitoxantrone | 1989 |
High dose chemotherapy in solid tumours in adults.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Breast Neoplasms; Carcinoma, Small Cell; Carmustine; Cell Separation; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Etoposide; Glioma; Humans; Lung Neoplasms; Male; Melanoma; Melphalan; Neoplasms; Testicular Neoplasms; Whole-Body Irradiation | 1986 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous | 1986 |
Indications for and benefits of intensive therapies in treatment of childhood cancers.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Methotrexate; Neoplasms; Osteosarcoma; Risk; Sarcoma, Ewing | 1986 |
[Ultrahigh-dosage cytostatics--their possible use in acute leukemias?].
Topics: Antineoplastic Agents; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Melphalan; Recurrence | 1987 |
Intensive chemotherapy for solid tumours--current clinical applications.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Forecasting; Humans; Melphalan; Neoplasms | 1982 |
Intensive therapy and autotransplantation in Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Digestive System Diseases; Etoposide; Heart Diseases; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lung Diseases; Melphalan; Multicenter Studies as Topic; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1994 |
Total body hyperthermia in combination with etoposide and melphalan in a child with acute myelomonocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Etoposide; Glucose; Humans; Hyperthermia, Induced; Leukemia, Myelomonocytic, Acute; Male; Melphalan; Time Factors | 1994 |
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Movement; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Kidney Diseases; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning | 1996 |
[Progress in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 1997 |
Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Melphalan; Middle Aged; Paraproteins; Remission Induction; Treatment Outcome; Vincristine | 1997 |
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Encephalitis; Etoposide; Female; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Injections, Spinal; Interferon-alpha; Interleukin-12; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Melphalan; Memory Disorders; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 1999 |
How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Brain Neoplasms; Child; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Male; Melphalan; Neuroectodermal Tumors, Primitive; Sarcoma, Ewing; Thiotepa; Vincristine; Whole-Body Irradiation | 2001 |
Multiple myeloma in elderly patients: presenting features and outcome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Comorbidity; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; France; Humans; Interferon-alpha; Life Tables; Lomustine; Male; Melphalan; Multiple Myeloma; Myeloma Proteins; Neoplasm Staging; Paraneoplastic Syndromes; Prednimustine; Prednisone; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Male; Melphalan; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Rhabdomyosarcoma; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Topotecan; Treatment Outcome; Vincristine | 2001 |
[Primary cardiac lymphoma: cytological diagnosis and treatment with response to polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrial Flutter; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Echocardiography, Transesophageal; Etoposide; Heart Failure; Heart Neoplasms; Heart Septum; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Immunocompetence; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Melphalan; Methotrexate; Middle Aged; Pleural Effusion; Prednisone; Remission Induction; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2002 |
Autologous stem cell transplantation in patients with mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Finland; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Life Tables; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Carmustine; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Retrospective Studies; Risk Factors; Sarcoma, Ewing; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2005 |
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials, Phase III as Topic; Etoposide; Female; Humans; Infusions, Intravenous; Lomustine; Lung Neoplasms; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ontario; Practice Guidelines as Topic; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Topotecan | 2007 |
Autologous stem cell transplantation for chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Melphalan; Neoplasm, Residual; Neoplasms, Second Primary; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2007 |
Treatment of Hodgkin lymphoma: the past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Lomustine; Mechlorethamine; Melphalan; Multicenter Studies as Topic; Neoplasm Staging; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Vinblastine; Vincristine; Vindesine | 2008 |
[Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Cytarabine; Dendritic Cell Sarcoma, Interdigitating; Drug Resistance, Neoplasm; Etoposide; Humans; Leg; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Soft Tissue Neoplasms; Tibia; Tomography, X-Ray Computed | 2009 |
Standard therapy of advanced Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Mechlorethamine; Melphalan; Methylprednisolone; Positron-Emission Tomography; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2009 |
Double high-dose chemotherapy and stem cell transplantation in adult Wilms' tumor.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cyclophosphamide; Etoposide; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Melphalan; Paclitaxel; Radiography; Salvage Therapy; Topotecan; Transplantation, Autologous; Wilms Tumor; Young Adult | 2010 |
Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.
Topics: Adult; Antineoplastic Agents; Child; Clinical Trials as Topic; Epirubicin; Etoposide; Humans; Melphalan; Molecular Targeted Therapy; Neoplasms; Topotecan | 2011 |
[Significance of intensified conditioning regimen for allogeneic hematopoietic stem cell transplantation for treatment of acute leukemias].
Topics: Acute Disease; Cyclophosphamide; Cytarabine; Etoposide; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Recurrence; Risk; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2011 |
Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2013 |
Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Dosage Calculations; Etoposide; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Myeloablative Agonists; Obesity; Transplantation Conditioning | 2014 |
Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy; Cytarabine; Disease-Free Survival; Etoposide; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Radiopharmaceuticals; Treatment Outcome | 2014 |
[Treatment strategy of Hodgkin lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuximab Vedotin; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Immunoconjugates; Mechlorethamine; Melphalan; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Rituximab; Vinblastine; Vincristine | 2014 |
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T
Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Diseases; Melphalan; Obesity; Renal Insufficiency, Chronic; Societies, Medical; Surveys and Questionnaires; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
[Sinusoidal obstruction syndrome after BeAM conditioning regiment for autologous stem cell transplantation: Imputability of bendamustine? Report of two cases and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous | 2018 |
Risk stratification of pulmonary toxicities in the combination of whole lung irradiation and high-dose chemotherapy for Ewing sarcoma patients with lung metastases: a review.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Drug Administration Schedule; Etoposide; Female; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Melphalan; Procedures and Techniques Utilization; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Respiratory Function Tests; Risk; Sarcoma, Ewing; Whole-Body Irradiation; Young Adult | 2020 |
166 trial(s) available for etoposide and melphalan
| Article | Year |
|---|---|
Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Male; Melphalan; Middle Aged; Recombinant Proteins; Recurrence; Transplantation, Autologous | 1992 |
High dose etoposide melphalan, total body irradiation and ABMT for acute myeloid leukemia in first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Whole-Body Irradiation | 1992 |
BEAM autografting in lymphoma--experience at one centre.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Rate; Transplantation, Autologous | 1992 |
Improved relapse free survival in patients with poor prognosis Ewing's sarcoma after consolidation with hyperfractionated total body irradiation and fractionated high dose melphalan followed by high dose etoposide and hematopoietic rescue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Combined Modality Therapy; Etoposide; Graft Survival; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Melphalan; Radiotherapy Dosage; Remission Induction; Sarcoma, Ewing; Survival Rate; Whole-Body Irradiation | 1991 |
GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic System; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation, Autologous | 1991 |
alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 1991 |
Intracavitary chemotherapy.
Topics: Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Catheters, Indwelling; Cisplatin; Clinical Trials as Topic; Cytarabine; Doxorubicin; Etoposide; Fluorouracil; Humans; Immunotherapy; Infusions, Parenteral; Melphalan; Methotrexate; Mitomycins; Mitoxantrone; Neoplasms; Organoplatinum Compounds | 1986 |
GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Stimulating Factors; Combined Modality Therapy; Cytarabine; Drug Evaluation; Etoposide; Granulocytes; Hodgkin Disease; Humans; Leukocyte Count; Macrophages; Melphalan; Neutropenia; Neutrophils; Postoperative Complications; Recombinant Proteins; Transplantation, Autologous | 1989 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous | 1986 |
Current results of a multicenter trial in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Random Allocation; Vincristine | 1986 |
Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Platelet Count | 1995 |
Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fever; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Melphalan; Neutropenia; Retrospective Studies; Salvage Therapy | 1995 |
Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Humans; Medroxyprogesterone Acetate; Megestrol; Megestrol Acetate; Melphalan; Middle Aged; Prospective Studies; Survival Rate | 1995 |
Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Remission Induction; Thrombocytopenia; Vincristine | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Prognosis; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous | 1995 |
High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Prognosis; Recurrence; Transplantation, Autologous | 1993 |
High-dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Child; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Follow-Up Studies; Humans; Infant; Melphalan; Neoplasm Recurrence, Local; Neuroblastoma; Radiotherapy, High-Energy; Remission Induction; Survival Rate | 1994 |
Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Intravenous; Melphalan; Middle Aged; Neoplasms; Retrospective Studies; Transplantation, Autologous | 1994 |
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Survival Rate | 1993 |
Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 1994 |
No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Melphalan; Middle Aged; Platelet Aggregation; Prednisone; Survival Rate | 1993 |
Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Risk Factors; Transplantation, Autologous | 1993 |
The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Risk; Survival Rate; Transplantation, Autologous | 1993 |
Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Melphalan; Middle Aged | 1995 |
Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Culture Techniques; Cells, Cultured; Combined Modality Therapy; Culture Media; Cyclophosphamide; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunomagnetic Separation; Leukapheresis; Lewis X Antigen; Melphalan; Middle Aged; Neutropenia; Tamoxifen; Thiotepa; Thrombocytopenia | 1996 |
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Life Tables; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Recombinant Proteins; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Infant; Infusions, Intravenous; Injections, Intravenous; Male; Melphalan; Neuroblastoma; Neutropenia; Remission Induction; Salvage Therapy; Stomatitis; Transplantation Conditioning; Vincristine | 1996 |
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Movement; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Kidney Diseases; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning | 1996 |
Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis | 1996 |
High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Chi-Square Distribution; Confidence Intervals; Diarrhea; Disease-Free Survival; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Herpes Zoster; Humans; Liver Neoplasms; Lung Neoplasms; Melphalan; Middle Aged; Neoplasm Staging; Survival Rate; Thiotepa; Treatment Outcome | 1996 |
Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cell Movement; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Lymphoma; Melphalan; Middle Aged; Phospholipid Ethers; Risk Factors; Transplantation Conditioning | 1996 |
High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Erythropoietin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hematopoietic System; Humans; Length of Stay; Melphalan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Recombinant Proteins; Survival Rate | 1997 |
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Neutropenia; Patient Selection; Recombinant Proteins; Thiotepa | 1997 |
A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Thiotepa; Transplantation, Autologous | 1997 |
Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Prospective Studies; Transplantation, Autologous | 1997 |
Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Cause of Death; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1997 |
A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Topics: Adult; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Filgrastim; Follow-Up Studies; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Leucovorin; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Prednisone; Recombinant Proteins; Treatment Outcome; Vincristine | 1997 |
Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Transplantation, Autologous | 1998 |
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Leukocyte Count; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies | 1998 |
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Treatment Outcome | 1998 |
Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan | 1998 |
Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Methotrexate; Methylprednisolone; Middle Aged; Mitomycins; Prednisone; Prospective Studies; Treatment Outcome; Vincristine | 1998 |
Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carmustine; Cell Separation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epirubicin; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Ifosfamide; Macrophages; Male; Melphalan; Neoplasms; Prednisolone; Vincristine | 1998 |
Total therapy with tandem transplants for newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Treatment Outcome; Vincristine | 1999 |
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Drug Resistance, Multiple; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Recurrence; Survival Analysis; Time Factors | 1999 |
Pilot study of the combination of melphalan, carboplatin and etoposide as a conditioning regimen for relapsed lymphoma patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Pilot Projects; Recurrence; Transplantation Conditioning | 1999 |
Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Recurrence; Survival Rate; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infections; Lung Diseases; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation, Autologous | 2000 |
High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis.
Topics: Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carmustine; CD4-CD8 Ratio; Cytarabine; Etoposide; Female; Fever; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Leukapheresis; Lymphocyte Subsets; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Multiple Sclerosis; Neutropenia; Prognosis; Severity of Illness Index | 2000 |
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2000 |
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous | 2000 |
Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Prednisone; Procarbazine; Prospective Studies; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2000 |
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Treatment Outcome | 2000 |
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine | 2000 |
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Granisetron; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lymphoma; Male; Melphalan; Nausea; Ondansetron; Serotonin Antagonists; Transplantation, Autologous; Tropisetron; Vomiting | 2000 |
A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Feasibility Studies; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Prospective Studies; Treatment Outcome | 2000 |
Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis.
Topics: Adrenal Cortex Hormones; Adult; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Magnetic Resonance Imaging; Melphalan; Middle Aged; Multiple Sclerosis; Patient Selection; T-Lymphocytes | 2001 |
High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Disease Progression; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Neoplasm Metastasis; Prognosis; Sarcoma, Ewing; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2001 |
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hodgkin Disease; Humans; Leukocyte Count; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Staging; Treatment Outcome | 2001 |
High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Longitudinal Studies; Melphalan; Middle Aged; Ovarian Neoplasms; Survival Rate; Treatment Outcome | 2001 |
Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Gadolinium; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Preoperative Care; Transplantation, Autologous; Treatment Outcome | 2001 |
Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma.
Topics: 3-Iodobenzylguanidine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Etoposide; Homovanillic Acid; Humans; Ifosfamide; Iodine Radioisotopes; Life Tables; Melphalan; Neoplasm Staging; Neuroblastoma; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Vanilmandelic Acid; Vincristine; Vindesine | 2001 |
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Mitoguazone; Recurrence; Salvage Therapy; Transplantation, Autologous; Vinblastine; Vinorelbine | 2002 |
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bronchiolitis Obliterans; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Kidney Diseases; Life Tables; Male; Melphalan; Neoplasm Metastasis; Radiotherapy, Adjuvant; Remission Induction; Rhabdomyosarcoma; Sepsis; Soft Tissue Neoplasms; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisolone; Prednisone; Prognosis; Survival Rate; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2000 |
Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
Topics: 3-Iodobenzylguanidine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Neuroblastoma; Pilot Projects; Radiopharmaceuticals; Transplantation, Autologous | 2002 |
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Mitoxantrone; Neuroectodermal Tumors, Primitive, Peripheral; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma; Survival Analysis; Thiotepa; Vincristine | 2002 |
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; DNA, Neoplasm; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy | 2002 |
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Blood Donors; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Graft vs Host Disease; Humans; Immunosuppression Therapy; Lymphocyte Transfusion; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Monitoring, Physiologic; Secondary Prevention; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2001 |
Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2002 |
A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's diseas
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hodgkin Disease; Humans; Melphalan; Prognosis; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2002 |
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Germany; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisolone; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Risk; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Melphalan; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Treatment Outcome | 2002 |
[Effectiveness of high-dose polychemotherapy and autologous hemopoietic cell transplantation in patients with low-grade non-Hodgkin lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chromatography, High Pressure Liquid; Etoposide; Hodgkin Disease; Humans; Life Expectancy; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Multiple Myeloma; Organophosphorus Compounds; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 2003 |
[Effectiveness of dose-intensive polychemotherapy with autologous hemopoietic cell transplantation for high-grade non-Hodgkin lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2003 |
BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Survival Rate; Transplantation, Autologous | 2003 |
Evaluation of relative anti-myeloma activity of high-dose melphalan followed by the first peripheral blood stem cell transplantation, as compared with the second transplantation, and to VAD chemotherapy.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bone Marrow Cells; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Flow Cytometry; Humans; Immunoglobulin G; Male; Melphalan; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Stem Cell Transplantation | 2003 |
High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2003 |
Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Data Collection; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Longitudinal Studies; Melphalan; Middle Aged; Remission Induction; Risk Factors; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2004 |
Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2004 |
The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neutropenia; Thrombocytopenia; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2004 |
Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Radioimmunotherapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2005 |
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Treatment Outcome; Vincristine | 2005 |
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Radiation-Protective Agents; Transplantation, Autologous | 2004 |
The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study.
Topics: Adult; Aged; Anti-Infective Agents, Local; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Mouth Mucosa; Mouthwashes; Peripheral Blood Stem Cell Transplantation; Povidone-Iodine; Sex Factors; Sodium Chloride; Stomatitis; Transplantation, Autologous | 2005 |
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2005 |
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Feasibility Studies; Female; Hodgkin Disease; Humans; Infusions, Intravenous; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2005 |
First-line autologous stem cell transplantation in primary CNS lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompetence; Lymphoma; Male; Melphalan; Middle Aged; Neurotoxicity Syndromes; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous | 2005 |
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Prednisone; Procarbazine; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2005 |
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Agents; Carboplatin; Child; Child, Preschool; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neuroblastoma; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2006 |
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Vincristine | 2006 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Remission Induction; Rituximab; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2006 |
Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Rituximab; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Transplantation, Autologous; Treatment Outcome | 2006 |
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Male; Melphalan; Middle Aged; Morbidity; Mortality; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous | 2006 |
High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Prognosis; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous | 2006 |
Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Melphalan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Treatment Outcome | 2006 |
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Germany; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 2007 |
Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Celiac Disease; Combined Modality Therapy; Cytarabine; Enteral Nutrition; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gastrointestinal Diseases; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Sepsis; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2007 |
High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Melphalan; Remission Induction; Transplantation Conditioning; Transplantation, Homologous | 2007 |
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Risk Assessment; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmustine; Cytarabine; Double-Blind Method; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous | 2008 |
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Epirubicin; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Infant; Kaplan-Meier Estimate; Male; Melphalan; Sarcoma; Soft Tissue Neoplasms; Thiotepa; Treatment Outcome; Vincristine | 2008 |
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2008 |
A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Etoposide; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hypocalcemia; Kidney Neoplasms; Melphalan; Neoplasms; Neuroblastoma; Pilot Projects; Recurrence; Risk Factors; Sarcoma; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Wilms Tumor | 2008 |
EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirubicin; Erythropoietin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukapheresis; Leukocyte Count; Leukocytes; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prospective Studies; Recombinant Proteins | 2009 |
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; Radiopharmaceuticals; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Vincristine | 2008 |
Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Double-Blind Method; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Mouthwashes; Phytohemagglutinins; Pilot Projects; Placebos; Recombinant Proteins; Stomatitis | 2009 |
Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG.
Topics: Adult; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft Rejection; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Horses; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis; Quality of Life; Rabbits; Transplantation Conditioning | 2010 |
Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Inflammation; Melphalan; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 2009 |
A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Melphalan; Thiotepa; Transplantation Conditioning | 2010 |
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Protein Kinases; Recurrence; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2009 |
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Feasibility Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Lymphoma; Male; Melphalan; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2010 |
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |
Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Predictive Value of Tests; Prednisolone; Prednisone; Proportional Hazards Models; Radiopharmaceuticals; Rituximab; Teniposide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult | 2010 |
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisolone; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vincristine; Young Adult | 2010 |
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Neutropenia; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous; Young Adult | 2010 |
BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Granisetron; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Paclitaxel; Treatment Outcome; Vomiting; Young Adult | 2011 |
Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; China; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuromyelitis Optica; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Spinal Cord; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Melphalan; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Sarcoma, Ewing; Vincristine; Young Adult | 2011 |
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Mucositis; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2011 |
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryotherapy; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Prospective Studies; Risk Factors; Stomatitis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Prospective Studies; Survival Rate; Transplantation, Autologous; Whole-Body Irradiation | 2011 |
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prospective Studies; Radioimmunotherapy; Recurrence; Rituximab; Salvage Therapy; Stem Cell Transplantation | 2011 |
Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America.
Topics: Antineoplastic Agents; Carboplatin; Child, Preschool; Etoposide; Female; Humans; Infant; Male; Melphalan; Neoplasm Metastasis; Retinoblastoma; South America; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2012 |
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2011 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Melphalan; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Transplantation, Autologous; Treatment Outcome; Vomiting | 2011 |
Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Phosphates; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mouthwashes; Multiple Myeloma; Stomatitis; Transplantation Conditioning; Treatment Outcome; Young Adult | 2011 |
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Odds Ratio; Prognosis; Proportional Hazards Models; Recurrence; Risk Factors; Sample Size; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Genes, myc; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Rituximab; Salvage Therapy; Transplantation, Autologous; Treatment Failure; Young Adult | 2012 |
Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cryopreservation; Cytarabine; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lomustine; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2012 |
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Rituximab; Survival Rate; Transplantation, Autologous | 2012 |
Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Radioimmunotherapy; Rituximab; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2012 |
Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Gene Amplification; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Risk Factors; Thiotepa; Transplantation Conditioning | 2012 |
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Prospective Studies; Radioimmunotherapy; Recurrence; Rituximab; Transplantation, Autologous; Young Adult | 2013 |
Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Ifosfamide; Male; Melphalan; Mesna; Neoplasm Staging; Prognosis; Prospective Studies; Sarcoma, Ewing; Sex Factors; Survival Rate; Vincristine; Young Adult | 2014 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous | 2014 |
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Prognosis; Radioimmunotherapy; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome | 2014 |
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Prednisone; Prognosis; Prospective Studies; Radiopharmaceuticals; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Patient Selection; Prospective Studies; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Young Adult | 2015 |
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Italy; Kaplan-Meier Estimate; Lomustine; Male; Melphalan; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prednisone; Procarbazine; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2016 |
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; North America; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2016 |
Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Positron-Emission Tomography; Prednisone; Retreatment; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2017 |
Incorporation of high-dose
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Humans; Induction Chemotherapy; Infant; Melphalan; Neuroblastoma; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous; Young Adult | 2017 |
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Young Adult | 2018 |
High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neuroblastoma; Retrospective Studies; Survival Rate; Thrombotic Microangiopathies; Transplantation, Autologous | 2018 |
Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Child; Child, Preschool; Comparative Genomic Hybridization; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Japan; Male; Melphalan; Neuroblastoma; Prospective Studies; Survival Rate; Treatment Outcome | 2018 |
R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Prednisone; Rituximab; Transplantation, Autologous; Vincristine; Young Adult | 2018 |
Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Progression-Free Survival; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult | 2019 |
Autologous peripheral blood stem cell transplantation for relapsed/refractory HIV-associated lymphoma: a phase II clinical study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Feasibility Studies; Humans; Lymphoma, AIDS-Related; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Peripheral Blood Stem Cell Transplantation; Safety; Survival Rate; Transplantation, Autologous | 2020 |
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Netherlands; Prednisone; Progression-Free Survival; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Failure; Vincristine; Young Adult | 2020 |
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Burkitt Lymphoma; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; HIV Infections; Humans; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Transplantation, Autologous | 2021 |
BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Etoposide; Humans; Lymphoma, Follicular; Melphalan; Prospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2021 |
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy | 2022 |
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Mul
Topics: Antineoplastic Combined Chemotherapy Protocols; Behavior Therapy; Busulfan; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Transplantation, Autologous | 2023 |
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Male; Melphalan; Prospective Studies; Sarcoma, Ewing; Vincristine | 2022 |
High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
Topics: Bendamustine Hydrochloride; Cytarabine; Drug Therapy, Combination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Ifosfamide; Melphalan; Sarcoma, Ewing; Vincristine | 2022 |
412 other study(ies) available for etoposide and melphalan
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Formazans; Glioma; Rats; Tubulin; Tumor Cells, Cultured | 1996 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.
Topics: Antineoplastic Agents; Benzylamines; Cell Line, Tumor; Computer Simulation; Drug Discovery; Humans; Protein Binding; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Total-body hyperthermia with and without chemotherapy for advanced human neoplasms.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Burns; Creatine Kinase; Electroencephalography; Etoposide; Female; Humans; Hyperthermia, Induced; L-Lactate Dehydrogenase; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Neoplasms; Peripheral Nervous System Diseases; Remission, Spontaneous; Tachycardia | 1979 |
Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion, Autologous; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Salvage Therapy; Whole-Body Irradiation | 1992 |
BEAM regimen and G-CSF in HTLV-I-associated T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia-Lymphoma, Adult T-Cell; Melphalan; Middle Aged | 1992 |
High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Gastrointestinal Diseases; Humans; Ifosfamide; Male; Melphalan; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Vincristine; Whole-Body Irradiation | 1992 |
Treatment of advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Infant; Melphalan; Neuroblastoma; Survival Rate; Vincristine | 1992 |
Toxicity of single-day high-dose vincristine, melphalan, etoposide and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Infant; Kidney; Melphalan; Neuroblastoma; Transplantation, Autologous; Vincristine | 1992 |
Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Gastrointestinal Diseases; Humans; Infant; Male; Melphalan; Neuroblastoma; Pilot Projects; Transplantation, Autologous; Vincristine | 1992 |
High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Transplantation, Autologous | 1992 |
Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Risk Factors; Time Factors | 1992 |
Acute transient parotitis after high dose etoposide and autologous bone marrow transplantation.
Topics: Acute Disease; Adult; Amylases; Bone Marrow Transplantation; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Melphalan; Parotitis | 1990 |
Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Male; Melphalan; Methotrexate; Prognosis; Recombinant Proteins; Remission Induction; Survival Rate; Transplantation, Autologous; Vincristine; Whole-Body Irradiation | 1991 |
Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Female; Male; Melphalan; Methyltransferases; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Oxygen; Rhabdomyosarcoma | 1991 |
Myeloablative combination chemotherapy without total body irradiation for neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Melphalan; Neuroblastoma; Pelvic Neoplasms; Radiotherapy Dosage; Retroperitoneal Neoplasms; Survival Rate; Thiotepa; Whole-Body Irradiation | 1991 |
Is treatment intensification by adding etoposide and carboplatin to fractionated total body irradiation and melphalan acceptable in children with solid tumors with respect to toxicity?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Humans; Infant; Melphalan; Neoplasms | 1991 |
Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cisplatin; Colony-Forming Units Assay; Cyclophosphamide; Etoposide; Fibrosarcoma; Hematopoietic Stem Cells; Indazoles; Male; Melphalan; Mice; Mice, Inbred C3H; Pentoxifylline; Sarcoma, Experimental | 1991 |
Autografting with bone marrow exposed to multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophosphamide in vitro.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow; Bone Marrow Transplantation; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Hematopoiesis; Humans; Infant; Melphalan; Neuroblastoma; Neutrophils; Thiotepa; Vincristine | 1990 |
BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies | 1990 |
[Relapsed stage I neuroblastoma successfully treated by allogeneic bone marrow transplantation in second remission: case report of a 7-year-old girl].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Child; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Melphalan; Neuroblastoma; Remission Induction; Whole-Body Irradiation | 1990 |
Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DNA, Neoplasm; Drug Synergism; Etoposide; Female; Male; Melphalan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Rhabdomyosarcoma; Transplantation, Heterologous | 1990 |
Pharmacokinetics of very high-dose oral melphalan in cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Marrow Transplantation; Carmustine; Etoposide; Female; Humans; Injections, Intravenous; Lymphoma; Male; Melanoma; Melphalan; Middle Aged; Time Factors | 1990 |
Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Epirubicin; Etoposide; Evaluation Studies as Topic; Hodgkin Disease; Humans; Male; Melphalan; Prednisone; Premedication; Remission Induction; Vincristine | 1990 |
Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Survival; Cyclophosphamide; Drug Combinations; Etoposide; Fibrosarcoma; Fluorocarbons; Hydroxyethyl Starch Derivatives; Male; Melphalan; Mice; Mice, Inbred C3H; Organoplatinum Compounds | 1990 |
[Kinetics of etoposide cytotoxicity against mouse P388 leukemia].
Topics: Animals; Bleomycin; Cell Cycle; Cell Survival; Cisplatin; Colony-Forming Units Assay; Cytarabine; Doxorubicin; Etoposide; Fluorouracil; Leukemia P388; Leukemia, Experimental; Melphalan; Mice; Peplomycin; Podophyllotoxin; Tumor Stem Cell Assay; Vinblastine | 1985 |
[Pharmacokinetics of high-dose melphalan (200 mg/m2) in a case of total renal insufficiency].
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Kidney Failure, Chronic; Male; Melphalan; Teratoma; Testicular Neoplasms | 1988 |
Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Melphalan; Organoplatinum Compounds; Prognosis; Radiotherapy Dosage; Remission Induction; Vincristine | 1989 |
Treatment of multiple myeloma by high dose chemotherapy, total body irradiation and autologous blood stem cell autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Etoposide; Evaluation Studies as Topic; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Remission Induction; Transplantation, Autologous; Whole-Body Irradiation | 1989 |
[Cellular pharmacokinetics of melphalan alone or in combination on human lymphoma or lymphoblasts].
Topics: Antimetabolites; Blastomeres; Burkitt Lymphoma; Buthionine Sulfoximine; Cell Line; Etoposide; Humans; Lymphocytes; Melphalan; Methionine Sulfoximine; Verapamil | 1989 |
High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged | 1989 |
Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance; Etoposide; Humans; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Vincristine | 1989 |
[High-doses chemotherapy followed by bone marrow autograft in the treatment of small cell bronchial cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Carmustine; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Melphalan; Procarbazine | 1987 |
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Lymphoma; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Thymoma; Thymus Neoplasms | 1988 |
Improved prognosis for children with stage IV neuroblastoma: high-dose melphalan and autologous unpurged marrow transplantation after aggressive surgery and short chemotherapy with cisplatinum and etoposide.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Infant; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Autologous; Tumor Lysis Syndrome | 1988 |
Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Ifosfamide; Lymphoma; Melphalan; Methotrexate; Middle Aged; Mitoguazone; Podophyllotoxin | 1988 |
Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Gastrointestinal Diseases; Humans; Infant; Infections; Melphalan; Neuroblastoma; Teniposide; Thoracic Neoplasms; Transplantation, Autologous; Vincristine | 1987 |
Comparison of the sensitivity of normal and leukaemic myeloid progenitors to in-vitro incubation with cytotoxic drugs: a study of pharmacological purging.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Cell Survival; Clone Cells; Cyclophosphamide; Cytarabine; Etoposide; Granulocytes; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Melphalan; Transplantation, Autologous; Tumor Cells, Cultured | 1987 |
A novel dye exclusion method for testing in vitro chemosensitivity of human tumors.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Doxorubicin; Drug Evaluation, Preclinical; Eosine Yellowish-(YS); Etoposide; Fluorouracil; Hematoxylin; Humans; Leukemia, Myeloid, Acute; Mechlorethamine; Melphalan; Neoplasms; Staining and Labeling | 1983 |
Drug testing using a soft agar stem cell assay on patient and xenograft tumor material.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cisplatin; Colony-Forming Units Assay; Drug Synergism; Etoposide; Female; Granulosa Cell Tumor; Humans; Melphalan; Methotrexate; Mice; Misonidazole; Neoplasm Transplantation; Neoplasms; Ovarian Neoplasms; Transplantation, Heterologous; Tumor Stem Cell Assay; Vinblastine | 1984 |
Perspectives for the use of high-dose chemotherapy in the treatment of solid malignant tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Etoposide; Humans; Melphalan; Neoplasms; Whole-Body Irradiation | 1984 |
Long-term survival associated with metastatic small cell carcinoma of the esophagus treated by chemotherapy, autologous bone marrow transplantation, and adjuvant radiation therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Esophageal Neoplasms; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lymphatic Metastasis; Melphalan; Prognosis; Radiotherapy Dosage; Transplantation, Autologous; Vincristine | 1994 |
The response of diffuse large cell and other intermediate grade non-Hodgkin's lymphomas to adriamycin containing combination chemotherapy.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Leucovorin; Lomustine; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melphalan; Methotrexate; Middle Aged; Phosphoramide Mustards; Prednisolone; Prednisone; Prognosis; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Vincristine | 1994 |
Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Pancytopenia; Prednisone; Procarbazine; Prospective Studies; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Vinblastine; Vincristine | 1994 |
Administration of three cytokines instead of bone marrow transplantation in an HIV+ patient with high-grade lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Cytokines; Doxorubicin; Drug Therapy, Combination; Erythropoietin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, AIDS-Related; Melphalan; Prednisolone; Vincristine | 1994 |
Visual hallucinations following treatment with vincristine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Etoposide; Hallucinations; Humans; Lymphoma, T-Cell; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisolone; Prednisone; Procarbazine; Salvage Therapy; Serotonin; Structure-Activity Relationship; Vincristine | 1994 |
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Bone Marrow Cells; Carboplatin; Carmustine; Cell Adhesion Molecules; Cell Movement; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Fluorouracil; Gene Expression; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; L-Selectin; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Neutrophils; Platelet Count; Podophyllotoxin; Receptors, Very Late Antigen; Thiotepa | 1995 |
[Secondary myeloid/natural killer cell acute leukemia appeared in multiple myeloma treated with melphalan].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Etoposide; Fatal Outcome; Female; Humans; Killer Cells, Natural; Leukemia, Myeloid, Acute; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisolone | 1995 |
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cell Survival; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Glyoxal; Graft Survival; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Prednimustine; Prednisolone; Prednisone; Procarbazine; Radiotherapy; Retrospective Studies; Salvage Therapy; Vinblastine; Vincristine | 1995 |
Severe esophageal stricture after autologous bone marrow transplant.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Esophageal Stenosis; Esophagitis; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Leukemia, Myeloid; Melphalan; Middle Aged | 1995 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukapheresis; Lymphocyte Count; Lymphocyte Subsets; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome; Vincristine | 1995 |
Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells.
Topics: Abelson murine leukemia virus; Antineoplastic Agents; Apoptosis; Cell Nucleus; DNA Damage; DNA Nucleotidylexotransferase; DNA, Neoplasm; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; HL-60 Cells; Humans; Hydroxyurea; Leukemia; Melphalan; Oncogene Proteins v-abl; Protein-Tyrosine Kinases; Recombinant Proteins; Tumor Cells, Cultured | 1995 |
High-dose chemotherapy with autologous bone marrow transplantation for refractory metastatic gestational trophoblastic disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Choriocarcinoma; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Hysterectomy; Melphalan; Pregnancy; Transplantation, Autologous; Trophoblastic Tumor, Placental Site; Uterine Neoplasms | 1995 |
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Lymphoma; Male; Melphalan; Middle Aged; Salvage Therapy; Time Factors | 1993 |
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Busulfan; Carmustine; Cell Count; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasms; Prognosis; Radiation Injuries; Treatment Outcome; Vincristine; Whole-Body Irradiation | 1995 |
Delayed neutrophil recovery after BEAM chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cell Count; Combined Modality Therapy; Cytarabine; Etoposide; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neutropenia; Opportunistic Infections; Survival Analysis | 1995 |
Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Camptothecin; Carmustine; Cell Cycle; Cell Death; Cell Line; Cisplatin; Cricetinae; Cricetulus; DNA Damage; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Synergism; Etoposide; Fibroblasts; Hydroxyurea; Lung; Melphalan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
Pregnancy after autologous bone marrow transplantation for malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infant, Newborn; Lymphoma, Large B-Cell, Diffuse; Mechlorethamine; Melphalan; Podophyllotoxin; Prednisone; Pregnancy; Pregnancy Outcome; Procarbazine; Remission Induction; Salvage Therapy; Vincristine | 1994 |
Quality and functional capacity of the bone marrow microenvironment of autologous blood stem cell transplantation (ABSCT) recipients.
Topics: Bone Marrow; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Connective Tissue; Cyclophosphamide; Cytarabine; Etoposide; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Multiple Myeloma; Transplantation, Autologous; Whole-Body Irradiation | 1994 |
Early myeloablative therapy for multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Melphalan; Middle Aged; Multiple Myeloma; Radiation Injuries; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thiotepa; Treatment Outcome; Vincristine; Whole-Body Irradiation | 1994 |
Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Follicle Stimulating Hormone; Humans; Leydig Cells; Luteinizing Hormone; Lymphoma; Male; Melphalan; Spermatozoa; Transplantation, Autologous | 1994 |
Successful bone marrow transplant for a patient with T-lymphoblastic lymphoma in second remission preconditioned by total-body irradiation plus melphalan and etoposide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclosporine; Etoposide; Graft vs Host Disease; Humans; Male; Melphalan; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Whole-Body Irradiation | 1994 |
Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cryopreservation; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis | 1994 |
Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Breast Neoplasms; Cisplatin; Clinical Protocols; Combined Modality Therapy; Cyclophosphamide; Etoposide; Feasibility Studies; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Multiple Myeloma; Neoplasm Metastasis; Retroviridae; Transfection; Transplantation, Autologous; Whole-Body Irradiation | 1993 |
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate | 1993 |
Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Child; Cohort Studies; Combined Modality Therapy; Cytokines; Etoposide; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Prognosis; Recurrence; Remission Induction; Sarcoma, Ewing; Survival Analysis; Whole-Body Irradiation | 1993 |
Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Enzyme-Linked Immunosorbent Assay; Etoposide; Gangliosides; Humans; Melphalan; Mice; Neoplasm Staging; Neuroblastoma; Prognosis; Radiotherapy Dosage; Survival Analysis; Survival Rate; Thiotepa | 1994 |
Salivary excretion of anticancer drugs.
Topics: Antineoplastic Agents; Doxorubicin; Drug Monitoring; Etoposide; Fluorouracil; Humans; Injections, Intravenous; Melphalan; Models, Biological; Parotid Gland; Saliva | 1993 |
High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Survival Rate | 1993 |
Growth and growth hormone secretion after bone marrow transplantation.
Topics: Bone Marrow Transplantation; Child; Child, Preschool; Clinical Protocols; Cyclophosphamide; Etoposide; Female; Growth; Growth Disorders; Growth Hormone; Humans; Infant; Insulin-Like Growth Factor I; Leukemia; Male; Melphalan; Radiotherapy Dosage; Whole-Body Irradiation | 1993 |
A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Non-Hodgkin; Macrophages; Male; Melphalan | 1995 |
Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinogens; Carcinoma; Cell Adhesion; Down-Regulation; Enzyme Activation; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Male; Melphalan; Phorbol Esters; Prostatic Neoplasms; Protein Kinase C; Tumor Cells, Cultured | 1996 |
The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marrow Transplantation; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Transplantation, Homologous | 1996 |
Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Bleomycin; Cell Adhesion; Cell Line; Cyclophosphamide; DNA Topoisomerases, Type II; DNA, Neoplasm; Dose-Response Relationship, Drug; Electrophoresis; Etoposide; Humans; Kinetics; Male; Melphalan; Molecular Weight; Nucleosomes; Prostatic Neoplasms; Tumor Cells, Cultured | 1996 |
High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Liver Function Tests; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Respiratory Function Tests; Retrospective Studies; Transplantation, Autologous | 1996 |
Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
Topics: Amides; Antineoplastic Agents; Aspartic Acid; Blotting, Western; Breast Neoplasms; Cell Cycle; Clone Cells; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Flow Cytometry; Gene Expression; Genes, p53; Humans; Immunohistochemistry; Melphalan; Mitoxantrone; Neoplasm Proteins; Nuclear Proteins; Phosphonoacetic Acid; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazoles; Ribonucleosides; Ribose; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1996 |
Kaposi's sarcoma after autologous bone marrow transplantation for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Fatal Outcome; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Immunocompromised Host; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Sarcoma, Kaposi; Skin Neoplasms; Transplantation, Autologous | 1996 |
Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Lymphocyte Count; Male; Melphalan; Mitoxantrone; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Vincristine; Whole-Body Irradiation | 1996 |
Successful mobilisation of blood stem cells following previous autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Hematopoietic Stem Cells; Humans; Ifosfamide; Leukapheresis; Lymphoma, Follicular; Male; Melphalan; Methotrexate; Podophyllotoxin; Prednisolone; Prednisone; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 1996 |
t(9;13)(q34;q12) chromosomal translocation persisting 4 years post autologous bone marrow transplantation for secondary AML despite morphological remission.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzene; Bone Marrow; Bone Marrow Transplantation; Carmustine; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 9; Combined Modality Therapy; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Melphalan; Myelodysplastic Syndromes; Neoplastic Stem Cells; Occupational Diseases; Occupational Exposure; Pancytopenia; Remission Induction; Solvents; Translocation, Genetic; Transplantation, Homologous | 1996 |
Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Blood Transfusion, Autologous; Bone Marrow; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Synergism; Epirubicin; Etoposide; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Injections, Subcutaneous; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Recombinant Proteins | 1996 |
Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged | 1996 |
Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carboplatin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasms; Patient Acceptance of Health Care; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1996 |
Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; DNA, Complementary; DNA, Neoplasm; Epirubicin; ErbB Receptors; Etoposide; Evaluation Studies as Topic; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunoenzyme Techniques; Immunomagnetic Separation; Keratins; Leukapheresis; Melphalan; Middle Aged; Neoplasm Proteins; Neoplastic Cells, Circulating; Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Transplantation Conditioning | 1997 |
Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Injections, Spinal; Lymphoma, B-Cell, Marginal Zone; Male; Melphalan; Methotrexate; Prednisone; Recurrence; Remission Induction; Retreatment; Salvage Therapy; Stomach Neoplasms; Transplantation Conditioning; Tumor Lysis Syndrome; Vincristine | 1997 |
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leucovorin; Leukapheresis; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Pilot Projects; Prednisone; Risk; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 1997 |
Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hemoglobins; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutrophils; Platelet Count; Transplantation Conditioning | 1997 |
Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methylprednisolone; Middle Aged; Myeloproliferative Disorders; Neutropenia; Salvage Therapy; Survival Rate; Time Factors | 1997 |
In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Topics: Aclarubicin; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Bone Marrow; Cell Survival; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Follow-Up Studies; Humans; Infant; Infant, Newborn; Life Tables; Melphalan; Methotrexate; Mitomycin; Mitoxantrone; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Recurrence; Remission Induction; Tumor Cells, Cultured; Vincristine | 1997 |
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Treatment Outcome | 1997 |
BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Prednisone; Survival Rate; Treatment Outcome; Vincristine | 1997 |
[High-dose chemotherapy with autologous stem cell rescue in patients with recurrent and high-risk pediatric brain tumors].
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Carboplatin; Child; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Risk Factors; Time Factors | 1997 |
[Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Prognosis; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Transplantation, Autologous | 1997 |
IFN-beta partially counteracts inhibition of natural killer activity induced by some antitumor agents.
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Cytotoxicity Tests, Immunologic; Distamycins; Doxorubicin; Etoposide; Immunosuppressive Agents; Interferon-beta; Killer Cells, Natural; Melphalan; Nitrogen Mustard Compounds; Recombinant Proteins | 1998 |
New clonal karyotypic abnormalities acquired following autologous bone marrow transplantation for acute myeloid leukemia do not appear to confer an adverse prognosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Combined Modality Therapy; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Retrospective Studies; Transplantation, Autologous; Whole-Body Irradiation | 1998 |
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Cell Separation; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; DNA Repair; DNA, Neoplasm; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Melphalan; Paclitaxel; Tamoxifen; Thioguanine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1998 |
Drug resistance in human neuroblastoma cell lines correlates with clinical therapy.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Melphalan; Neuroblastoma; Tumor Cells, Cultured | 1997 |
Discrimination between genotoxicity and cytotoxicity in the induction of DNA double-strand breaks in cells treated with etoposide, melphalan, cisplatin, potassium cyanide, Triton X-100, and gamma-irradiation.
Topics: Antineoplastic Agents; Cell Line; Cisplatin; DNA Damage; DNA Fragmentation; Electrophoresis, Gel, Pulsed-Field; Etoposide; Gamma Rays; Humans; Melphalan; Mutagens; Octoxynol; Potassium Cyanide | 1998 |
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoguazone; Salvage Therapy; Time Factors | 1998 |
Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Pilot Projects; Prednisone; Survival Rate; Transplantation, Autologous; Vincristine | 1998 |
High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Polyps; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Prednisone; Transplantation, Autologous; Vincristine | 1998 |
Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies | 1998 |
Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colony-Forming Units Assay; Cytarabine; Dexamethasone; Etoposide; Female; Filgrastim; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Lymphoma; Male; Melphalan; Middle Aged; Recombinant Proteins; Retrospective Studies | 1998 |
High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kidney Neoplasms; Male; Melphalan; Neoplasm Recurrence, Local; Wilms Tumor | 1998 |
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carrier Proteins; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; DNA Adducts; DNA Damage; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Humans; Melphalan; Methylnitronitrosoguanidine; Mutagenesis; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Thioguanine; Tumor Cells, Cultured | 1997 |
High-dose sequential chemotherapy with autologous blood stem cell rescue for relapsed or resistant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Stem Cells | 1998 |
Flow cytometric detection of p53 protein after incubation of a pre-B cell line with antitumor agents.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Separation; DNA Fragmentation; Etoposide; Flow Cytometry; Humans; Immunoglobulin G; Melphalan; Time Factors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chronic Disease; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Radiotherapy; Recurrence; Survival Analysis; Transplantation, Autologous | 1999 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Chlorambucil; Cohort Studies; Combined Modality Therapy; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Infant; Leukemia, Myeloid; Life Tables; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Prednisolone; Prednisone; Procarbazine; Retrospective Studies; Risk; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Growth in children with poor-risk neuroblastoma after regimens with or without total body irradiation in preparation for autologous bone marrow transplantation.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Body Height; Bone Marrow Transplantation; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Etoposide; Growth; Human Growth Hormone; Humans; Infant; Melphalan; Neuroblastoma; Retrospective Studies; Risk Factors; Thyroxine; Transplantation, Autologous; Whole-Body Irradiation | 1999 |
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Immunization, Passive; Interleukin-2; Male; Melphalan; Middle Aged; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Selective increase in cellular A beta 42 is related to apoptosis but not necrosis.
Topics: Amyloid beta-Peptides; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Etoposide; Guinea Pigs; Humans; Hydrogen Peroxide; Immunohistochemistry; In Situ Nick-End Labeling; L-Lactate Dehydrogenase; Melphalan; Necrosis; Peptide Fragments; Reactive Oxygen Species; Sodium Azide | 2000 |
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation, Autologous | 2000 |
Oxidative burst measurement in patients treated with cytostatics: influence of G-CSF and role as a prognostic factor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Escherichia coli; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Prognosis; Respiratory Burst; Tetradecanoylphorbol Acetate | 2000 |
High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Cystadenocarcinoma; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Laparotomy; Melphalan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Reoperation; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Autologous | 2000 |
Expression of CD11b/CD18 on neutrophils after consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; CD18 Antigens; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Macrophage-1 Antigen; Male; Melphalan; Middle Aged; Neoplasm Proteins; Neutropenia; Recombinant Proteins; Remission Induction | 2000 |
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; L-Lactate Dehydrogenase; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation, Autologous | 2000 |
Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Risk Factors; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2000 |
[The 1st results of the combined therapy of recurrent and refractory forms of lymphogranulomatosis (polychemotherapy, radiation therapy and the removal of the residual mediastinal formation)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cytarabine; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Male; Mediastinal Neoplasms; Melphalan; Middle Aged; Neoplasm, Residual; Prognosis; Radiotherapy, Adjuvant; Recurrence; Salvage Therapy | 2000 |
Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Antineoplastic Agents; Bone Marrow Cells; Cell Division; Chemokine CCL4; Cisplatin; Colony-Forming Units Assay; Culture Media, Conditioned; Cytarabine; Etoposide; Female; Growth Inhibitors; Hematopoietic Stem Cells; Macrophage Inflammatory Proteins; Melphalan; Mice; Mice, Inbred BALB C; Pentoxifylline; Spleen; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2000 |
Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2000 |
Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient.
Topics: Antigens, Surface; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blotting, Western; Bone Marrow; Cell Division; Clone Cells; Etoposide; Female; Humans; Immunophenotyping; Interferon-gamma; Interleukin-6; Japan; Melphalan; Middle Aged; Multiple Myeloma; Pleural Effusion; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2000 |
Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Time Factors; Transplantation Conditioning | 2000 |
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Purging; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclophosphamide; Cystitis; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Infections; Leucovorin; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Pilot Projects; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2000 |
Rescue of haemopoiesis by a combination of growth factors including stem-cell factor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Cytarabine; Epoetin Alfa; Erythrocyte Transfusion; Erythropoietin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Lymphoma, Non-Hodgkin; Melphalan; Platelet Transfusion; Recombinant Proteins; Treatment Outcome | 2000 |
Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carmustine; Cefotaxime; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Idarubicin; Immunocompromised Host; Immunosuppressive Agents; Levofloxacin; Lymphoma, T-Cell; Male; Melphalan; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Prednisone; Recurrence; Rifampin; Splenectomy; Streptococcus pneumoniae; Transplantation Conditioning; Vincristine | 2000 |
High-dose chemotherapy and autologous stem cell rescue for acute myeloid leukemia remains a safe, effective, and valid option.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Melphalan; Middle Aged; Platelet Count; Recombinant Proteins; Reproducibility of Results; Safety; Survival Rate; Transplantation, Autologous | 2000 |
Characterization of DNA fragmentation events caused by genotoxic and non-genotoxic agents.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cytarabine; DNA; DNA Damage; DNA Fragmentation; Electrophoresis, Gel, Pulsed-Field; Enzyme Inhibitors; Etoposide; Formamides; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Melphalan; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2001 |
Complete remission of generalized relapsed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type of the gastrointestinal tract after high-dose chemotherapy and autologous peripheral stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Gastrointestinal Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Melphalan; Middle Aged; Remission Induction; Transplantation, Autologous | 2000 |
[Role of high-dose BEAM-chemotherapy and autologous hemopoietic stem cell transplantation in the treatment of drug-resistant Hodgkin disease].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2000 |
Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Prognosis; Radiation Pneumonitis; Retrospective Studies; Transplantation, Autologous; Whole-Body Irradiation | 2001 |
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Carboplatin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Multiple; Etoposide; Gene Amplification; Humans; Melphalan; Mutation; Neuroblastoma; Nuclear Proteins; Oncogene Proteins, Viral; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Repressor Proteins; Transcriptional Activation; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome | 2001 |
Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents.
Topics: 3T3 Cells; Alkylating Agents; Animals; Antimony; Blotting, Southern; Cells, Cultured; Chlorambucil; Cisplatin; Cloning, Molecular; DNA, Complementary; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Fibroblasts; Flow Cytometry; Friend murine leukemia virus; Genetic Therapy; Genetic Vectors; Genome, Viral; Glutamate-Cysteine Ligase; Glutathione; Hematopoietic Stem Cells; Humans; Inhibitory Concentration 50; Male; Melphalan; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Multidrug Resistance-Associated Proteins; Retroviridae; RNA; RNA, Messenger; Terminal Repeat Sequences; Transduction, Genetic; Viral Envelope Proteins | 2001 |
Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Fluorouracil; Imidazoles; Mammary Neoplasms, Experimental; Melphalan; Mice; Mice, Inbred BALB C; Paclitaxel; Quinolines; Tirapazamine; Triazines; Tumor Cells, Cultured | 2001 |
Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation.
Topics: Adenosine Triphosphate; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Buthionine Sulfoximine; Camptothecin; Cell Death; Cisplatin; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Enzyme Inhibitors; Etoposide; Flow Cytometry; Glutathione; Humans; Hydrogen Peroxide; Hypoxia; Immunoblotting; Melphalan; Membrane Potentials; Mitochondria; Monocytes; Necrosis; Nucleic Acid Synthesis Inhibitors; Oxygen; Radiation-Protective Agents; Reactive Oxygen Species; Spectrometry, Fluorescence; Time Factors; Topoisomerase I Inhibitors; U937 Cells | 2001 |
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease-Free Survival; Doxorubicin; Etoposide; False Negative Reactions; False Positive Reactions; Fibrosis; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Life Tables; Mediastinal Neoplasms; Melphalan; Neoplasm Recurrence, Local; Predictive Value of Tests; Prednisone; Procarbazine; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Tomography, Emission-Computed; Transplantation, Autologous; Vinblastine; Vincristine | 2001 |
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Topics: Adolescent; Alkylating Agents; Area Under Curve; Bayes Theorem; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Genetic Diseases, Inborn; Graft Survival; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Incidence; Infant; Life Tables; Male; Melphalan; Prospective Studies; Severe Combined Immunodeficiency; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2001 |
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infections; Male; Melphalan; Middle Aged; Neutropenia; Radiotherapy, Adjuvant; Retrospective Studies; Risk; Safety; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Conditioning; Treatment Outcome | 2001 |
A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Lung Diseases, Fungal; Male; Melphalan; Neoplasm Recurrence, Local; Opportunistic Infections; Pneumonia, Bacterial; Pneumonia, Pneumocystis; Prednisone; Procarbazine; Salvage Therapy; Skin; Transplantation, Homologous; Vinblastine; Vincristine | 2001 |
Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Blotting, Western; Cell Survival; CHO Cells; Chromosomes; Cricetinae; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Humans; Melphalan; Mutation; Razoxane; Sister Chromatid Exchange; Thiobarbiturates; Time Factors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2002 |
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Prognosis; Radiopharmaceuticals; Survival Analysis; Survival Rate; Tomography, Emission-Computed; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 2002 |
Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Chromosomes, Human, Pair 3; Cyclophosphamide; Cytarabine; Disease-Free Survival; DNA Mutational Analysis; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Genes, bcl-2; Humans; Life Tables; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Point Mutation; Prednisolone; Prednisone; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogenes; Transcription Factors; Treatment Outcome; Vincristine | 2002 |
Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Japan; Melphalan; Myeloablative Agonists; Neuroblastoma; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Treatment Outcome; Universities | 2001 |
Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Life Tables; Male; Melphalan; Mercaptopurine; Middle Aged; Neoplasm Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2000 |
Influence of phenytoin on the disposition of irinotecan: a case report.
Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Disease Progression; Drug Interactions; Enzyme Induction; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Melphalan; Mixed Function Oxygenases; Neoplasm Recurrence, Local; Ondansetron; Phenobarbital; Phenytoin; Pineal Gland; Pinealoma; Prodrugs; Salvage Therapy; Seizures | 2002 |
Acute myocardial ischemia after high-dose therapy with BEAM regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Immunoblastic Lymphadenopathy; Melphalan; Middle Aged; Myocardial Ischemia; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2002 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation.
Topics: Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Radionuclide Imaging; Stem Cell Transplantation | 2002 |
[Salvage thermochemotherapy in advanced refractory malignant tumors in children].
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Humans; Hyperthermia, Induced; Interleukin-2; Male; Melphalan; Monitoring, Immunologic; Neoplasms; Neuroleptanalgesia; Salvage Therapy; Time Factors; Vincristine | 2002 |
High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Germany; Hematologic Diseases; Humans; Ifosfamide; Infant; Kidney Diseases; Kidney Neoplasms; Life Tables; Lung Neoplasms; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Prognosis; Stomatitis; Survival Analysis; Thiotepa; Transplantation, Autologous; Wilms Tumor | 2002 |
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytokines; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; L-Lactate Dehydrogenase; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2003 |
High-dose chemotherapy and autologous peripheral blood stem cell rescue in a patient with pleuropulmonary blastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Melphalan; Pulmonary Blastoma; Radiography; Transplantation, Autologous; Treatment Outcome | 2003 |
Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.
Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Nephrotic Syndrome; Transplantation, Autologous | 2003 |
[Foliculitis in a patient with Hodkins disease].
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cytarabine; Dacarbazine; Dermatomycoses; Dexamethasone; Doxorubicin; Etoposide; Folliculitis; Hodgkin Disease; Humans; Itraconazole; Malassezia; Male; Melphalan; Opportunistic Infections; Vinblastine | 2003 |
Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation, Autologous | 2003 |
BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2003 |
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Prognosis; Transplantation, Autologous; Treatment Outcome | 2003 |
High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Sarcoma, Ewing; Survival Analysis; Whole-Body Irradiation | 2003 |
Construction of a dual beam heated infrared cell.
Topics: Carmustine; Etoposide; Melphalan; Spectrophotometry | 1953 |
[Some improvements to our technic of cross beam centering by moulded apparatus].
Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Radiotherapy | 1953 |
[Utilization of contiguous orthogonal beams in the treatment of semi-deep-seated tumors].
Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms | 1953 |
Influence of beam trypsin inhibitors on thromboplastic properties of trypsin and hypochlorite-treated trypsin.
Topics: Carmustine; Etoposide; Hypochlorous Acid; Melphalan; Thromboplastin; Trypsin; Trypsin Inhibitors | 1954 |
Convergent beam roentgen tube.
Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Radiotherapy | 1955 |
[Determination of the mean guide beam in pendulum radiation].
Topics: Carmustine; Etoposide; Humans; Melphalan; Radiation; Radiotherapy | 1954 |
[The effects of changed spacer tubes of the convergent beam irradiator].
Topics: Carmustine; Etoposide; Humans; Inhalation Spacers; Melphalan; Radiotherapy | 1954 |
Preliminary experiences with a 50 gram converging beam radium unit.
Topics: Carmustine; Cytarabine; Etoposide; Melphalan; Radium | 1955 |
Some measurements of scattered radiation from roentgen diagnostic beams.
Topics: Carmustine; Etoposide; Melphalan; Radiation; X-Rays | 1956 |
[Contribution to the study of convergence beam radiotherapy].
Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radiotherapy | 1956 |
Cobalt 60 beam therapy: some impressions after five years.
Topics: Carmustine; Cobalt; Cobalt Radioisotopes; Etoposide; Humans; Melphalan; Neoplasms; Radioactivity | 1957 |
Limitation of the primary beam in chest radiography.
Topics: Carmustine; Etoposide; Humans; Melphalan; Radiography, Thoracic | 1957 |
[Exact focus adjustment in moving-beam irradiation].
Topics: Adaptation, Psychological; Carmustine; Etoposide; Humans; Melphalan; Radiotherapy | 1957 |
[Centering of the beam in pendulum cyclotherapy and in convergent pendulum cyclotherapy].
Topics: Carmustine; Cytarabine; Etoposide; Melphalan; Radiotherapy | 1958 |
The relative biological effectiveness of external beams of ionizing radiations.
Topics: Carmustine; Etoposide; Humans; Melphalan; Radiation Effects; Radiation, Ionizing; Relative Biological Effectiveness | 1958 |
[Stratigraphy with thick and thin layers in various changes of the beam direction].
Topics: Carmustine; Cytarabine; Etoposide; Melphalan; Radiography | 1961 |
Beam flatteners for a teletherapy unit.
Topics: Carmustine; Cytarabine; Equipment and Supplies; Etoposide; Humans; Melphalan; Radiotherapy | 1961 |
[Isodoses in moving beam therapy].
Topics: Carmustine; Etoposide; Humans; Melphalan; Radiotherapy | 1962 |
Oblique variation of cross-table lateral (horizontal beam) myelography.
Topics: Carmustine; Etoposide; Intervertebral Disc Displacement; Melphalan; Myelography; Spinal Cord | 1962 |
[Beam focus radiography and beam focus solidography studies on telecobalttherapy 24, report studies on rotatory comformation radiotherapy. 13].
Topics: Cobalt Isotopes; Etoposide; Melphalan; Radioisotope Teletherapy; Research | 1962 |
A method of multilead D.C. registration on the one-beam oscilloscope by the chopping technique.
Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Oscillometry | 1961 |
Our experience with cobalt beam unit GUT-CO-400-2.
Topics: Cobalt; Cobalt Isotopes; Etoposide; Melphalan; Neoplasms | 1963 |
Moving beam irradiation in orthovoltage radiotherapy.
Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Radiotherapy | 1962 |
Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Neutropenia; Recurrence; Remission Induction; Thrombocytopenia; Tomography, X-Ray Computed; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2003 |
Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; B7-1 Antigen; Buthionine Sulfoximine; Carboplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Glutathione; Green Fluorescent Proteins; Humans; Lentivirus; Luminescent Proteins; Melphalan; Mutation; Neuroblastoma; Oxidative Stress; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Safety; Salvage Therapy; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2003 |
Annexin-I expression modulates drug resistance in tumor cells.
Topics: Annexin A1; Annexins; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Northern; Cell Line, Tumor; Cloning, Molecular; DNA, Complementary; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Library; HeLa Cells; Humans; Melphalan; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Open Reading Frames; Protein Biosynthesis; RNA; Transcription, Genetic; Transfection | 2004 |
A new roentgen-ray beam director for precision radiation therapy.
Topics: Carmustine; Etoposide; Melphalan; X-Ray Therapy | 1951 |
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Salvage Therapy; Treatment Outcome | 2004 |
Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Camptothecin; Carrier Proteins; Cell Line; Cisplatin; DNA Repair; Drug Screening Assays, Antitumor; Etoposide; Furocoumarins; Humans; Inhibitory Concentration 50; Melphalan; Mitomycin; MutL Protein Homolog 1; Neoplasm Proteins; Nitrosourea Compounds; Nuclear Proteins | 2004 |
Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kidney Neoplasms; Male; Melphalan; Neoplasm Recurrence, Local; Survival Analysis; Thiotepa; Transplantation, Autologous; Treatment Outcome; Wilms Tumor | 2004 |
High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Therapy, Combination; Erythropoietin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Survival Rate; Time Factors | 2004 |
The technique and results of treatment of cancer of the tongue with a 10 gram radium beam unit.
Topics: Etoposide; Humans; Melphalan; Neoplasms; Radium; Tongue; Tongue Neoplasms | 1950 |
Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Chromones; Cisplatin; Comet Assay; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Etoposide; Gefitinib; Humans; Melphalan; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors | 2004 |
Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ("Yasmine").
Topics: Adult; Androstenes; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Contraceptives, Oral, Synthetic; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Immunotherapy; International Normalized Ratio; Lynestrenol; Melphalan; Mineralocorticoid Receptor Antagonists; Risk; Risk Factors; Time Factors; Venous Thrombosis; Warfarin | 2005 |
Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms' tumor and a novel alteration in intron 1 of the WT1 gene.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Etoposide; Genes, Wilms Tumor; Germ-Line Mutation; Humans; Kidney Neoplasms; Male; Melphalan; Middle Aged; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Wilms Tumor | 2004 |
Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Bone Marrow Transplantation; Carmustine; Chemotherapy, Adjuvant; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2005 |
[Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Treatment Outcome | 2004 |
Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Salvage Therapy; Transplantation, Autologous; Transplants | 2005 |
Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Medical Oncology; Melphalan; Middle Aged; Prednisolone; Prognosis; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2005 |
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome | 2005 |
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Chlorambucil; Cisplatin; Cross-Linking Reagents; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Fanconi Anemia Complementation Group C Protein; Fanconi Anemia Complementation Group G Protein; Fanconi Anemia Complementation Group Proteins; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Melphalan; Mice; Mice, Nude; Mitomycin; Mutation; Paclitaxel; Pancreatic Neoplasms; Time Factors; Vinblastine; Xenograft Model Antitumor Assays | 2005 |
Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2006 |
High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Topics: Adolescent; Adult; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Infant; Male; Melphalan; Mice; Neuroblastoma; Retrospective Studies; Thiotepa; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2007 |
Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Incidence; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Oral Ulcer; Peripheral Blood Stem Cell Transplantation; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Sex Factors; Stomatitis; Transplantation, Autologous | 2006 |
Thalidomide for the treatment of leptomeningeal multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Immunoglobulin G; Melphalan; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Prednisolone; Prednisone; Thalidomide; Vindesine | 2006 |
High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Busulfan; Combined Modality Therapy; Disease Progression; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neoplasm Recurrence, Local; Sarcoma, Ewing; Treatment Outcome | 2006 |
Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Etoposide; Family; Graft vs Host Disease; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Magnetic Resonance Imaging; Male; Melphalan; Methotrexate; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2006 |
Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administration Schedule; Etoposide; Hodgkin Disease; Humans; Melphalan; Recurrence; Salvage Therapy | 2006 |
Successful treatment of a patient with POEMS syndrome by tandem high-dose chemotherapy with autologous CD34+ purged stem cell rescue.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Dexamethasone; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; POEMS Syndrome; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
The effect of intracellular ascorbate on the susceptibility of HL60 and Jurkat cells to chemotherapy agents.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Cell Count; Dehydroascorbic Acid; Drug Resistance, Neoplasm; Etoposide; HL-60 Cells; Humans; Jurkat Cells; Melphalan; Oxides | 2006 |
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Prospective Studies; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous; Vinblastine; Vinorelbine | 2007 |
Chemotherapy disrupts activity of translational regulatory proteins in bone marrow stromal cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cell Cycle Proteins; Cell Line; Cyclophosphamide; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Etoposide; Humans; Matrix Metalloproteinase 2; Melphalan; Mice; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Ribosomal Protein S6; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Stromal Cells; Structure-Activity Relationship; TOR Serine-Threonine Kinases | 2006 |
High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2007 |
Four-color flow cytometric analysis of myeloma plasma cells.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Cells; Combined Modality Therapy; Dexamethasone; Doxorubicin; Etoposide; Female; Flow Cytometry; Humans; Immunophenotyping; Male; Melphalan; Middle Aged; Multiple Myeloma; Staining and Labeling; Stem Cell Transplantation; Vincristine | 2006 |
Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Registries; Remission Induction; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; United Kingdom; Whole-Body Irradiation | 2006 |
Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carmustine; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infusions, Intravenous; Male; Melphalan; Mexico; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation, Autologous; Treatment Outcome | 2007 |
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Infection Control; Kaplan-Meier Estimate; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Postoperative Care; Retrospective Studies; Risk; Salvage Therapy; Sarcoma, Ewing; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vincristine | 2007 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine | 2008 |
Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Transplantation, Autologous | 2007 |
Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, Combination; Etoposide; Female; Graft Survival; Histiocytosis, Langerhans-Cell; Humans; Infant; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Melphalan; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vinblastine | 2007 |
High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Data Interpretation, Statistical; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Melphalan; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italian
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Rituximab; Transplantation, Autologous; Treatment Outcome | 2007 |
[Nutritional pathway for autologous stem cell transplantation].
Topics: Antineoplastic Agents, Alkylating; Body Weight; Carboplatin; Critical Pathways; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Melphalan; Multiple Myeloma; Parenteral Nutrition, Total; Transplantation Conditioning; Transplantation, Autologous | 2007 |
[Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Lymph Nodes; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Remission Induction; Rituximab; Treatment Outcome; Vinblastine; Vincristine | 2007 |
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Cell Survival; Dipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Immunoenzyme Techniques; Male; Melphalan; Mice; Molecular Structure; Neovascularization, Pathologic; Neuroblastoma; Prodrugs; Rats; Rats, Nude; Tumor Cells, Cultured; Vincristine | 2007 |
[Treatment and survival of multiple myeloma patients on programmed hemodialysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Renal Dialysis; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
[Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Transplantation, Autologous | 2007 |
Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Infant; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Nimustine; Recurrence; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2007 |
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Etoposide; Female; Humans; Immunoblastic Lymphadenopathy; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Treatment Outcome | 2008 |
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Medical Audit; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Stomatitis; Transplantation Conditioning; Transplantation, Autologous | 2008 |
Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells.
Topics: Adult; Alkalosis, Respiratory; Amnesia, Retrograde; Amnesia, Transient Global; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Confusion; Cryoprotective Agents; Cytarabine; Dacarbazine; Dexamethasone; Dimethyl Sulfoxide; Doxorubicin; Etoposide; Hippocampus; Hodgkin Disease; Humans; Hyperventilation; Ifosfamide; Magnetic Resonance Imaging; Male; Melphalan; Paresthesia; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Vinblastine; Vision Disorders | 2008 |
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
Topics: Acute Disease; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome | 2008 |
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Time Factors; Transplantation, Autologous; Treatment Outcome | 2008 |
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Italy; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rituximab; Survival Rate; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2008 |
Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Etoposide; Hepatic Veno-Occlusive Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2008 |
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carmustine; Chi-Square Distribution; Cohort Studies; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Mucositis; Recurrence; Risk; Statistics, Nonparametric; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2008 |
The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Male; Medical Audit; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Risk Factors; Stem Cell Transplantation; Stomatitis; Transplantation Conditioning | 2009 |
Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Carmustine; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Neutropenia; Prospective Studies; Risk Factors; Rituximab; Vidarabine; Young Adult | 2009 |
The development of a beam-walking test and its use in measuring development of balance in children.
Topics: Carmustine; Child; Cytarabine; Etoposide; Growth and Development; Melphalan; Walking | 1947 |
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2008 |
Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Fluorouracil; Focal Nodular Hyperplasia; Granulocyte Colony-Stimulating Factor; Hepatectomy; Hepatoblastoma; Humans; Ifosfamide; Immunoglobulin G; Incidental Findings; Liver Neoplasms; Male; Melphalan; Mesna; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Neuroblastoma; Radiotherapy, Adjuvant; Tomography, X-Ray Computed; Vincristine | 2008 |
Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation.
Topics: Acyclovir; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carmustine; Cisplatin; Colitis; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Intestinal Pseudo-Obstruction; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Postoperative Complications; Prednisolone; Rituximab; Transplantation, Autologous; Vincristine; Virus Activation | 2009 |
Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; HIV Infections; Humans; Lymphoma, AIDS-Related; Male; Melphalan; Nitrosourea Compounds; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2009 |
delta-Aminolevulinate dehydratase activity and oxidative stress during melphalan and cyclophosphamide-BCNU-etoposide (CBV) conditioning regimens in autologous bone marrow transplantation patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Biomarkers; Bone Marrow Transplantation; Carmustine; Case-Control Studies; Cyclophosphamide; Etoposide; Humans; Lipid Peroxidation; Male; Melphalan; Middle Aged; Oxidative Stress; Porphobilinogen Synthase; Reactive Oxygen Species; Sulfhydryl Compounds; Transplantation Conditioning; Transplantation, Autologous | 2009 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mucositis; Multiple Myeloma; Neoplasms; Severity of Illness Index; Whole-Body Irradiation; Young Adult | 2009 |
Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Kidney Neoplasms; Male; Melphalan; Prognosis; Rhabdoid Tumor; Survival Rate; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine | 2009 |
Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation, Autologous; Whole-Body Irradiation; Young Adult | 2009 |
[One hundred fifty autologous peripheral haemopoietic stem cell transplantations and their lessons].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hungary; International Cooperation; Kaplan-Meier Estimate; Leiomyosarcoma; Lymphoma, Non-Hodgkin; Melphalan; Multiple Myeloma; Nitrosourea Compounds; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2009 |
Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Italy; Lymph Nodes; Male; Melphalan; Middle Aged; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2002 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Manitoba; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Radiation Pneumonitis; Retrospective Studies; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation; Young Adult | 2010 |
Absorption measurements for broad beams of 1 and 2 megavolt roentgen rays.
Topics: Carmustine; Etoposide; Melphalan; Radiation; X-Rays | 1946 |
A double-beam, percent transmission recording infra-red spectrophotometer.
Topics: Carmustine; Etoposide; Humans; Melphalan; Spectrophotometry | 1947 |
A comparison of the cytogenetic alterations and global DNA hypomethylation induced by the benzene metabolite, hydroquinone, with those induced by melphalan and etoposide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cells, Cultured; Chromosomes, Human; DNA Methylation; Etoposide; Humans; Hydroquinones; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Lymphocytes; Melphalan; Mutagens | 2010 |
High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Kaplan-Meier Estimate; Male; Melphalan; Multiple Sclerosis; Treatment Outcome | 2010 |
Renal impairment due to white-cell lysis after G-CSF and chemotherapy during pediatric autologous stem cell transplantation.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Combined Modality Therapy; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Tumor Lysis Syndrome | 2010 |
Simultaneous bilateral spontaneous pneumothorax following high-dose chemotherapy and bone marrow transplantation for mantle cell lymphoma without evidence of pulmonary disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Lung Diseases; Lymphoma, Mantle-Cell; Melphalan; Middle Aged; Pneumothorax; Prognosis | 2010 |
Successful treatment of late, recurrent wilms tumor with high-dose chemotherapy and autologous stem cell rescue in third complete response.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Combined Modality Therapy; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Male; Melphalan; Neoplasm Recurrence, Local; Salvage Therapy; Wilms Tumor | 2010 |
Second high-dose chemotherapy intensification followed by hematopoietic stem cell transplantation applying a novel high-dose topotecan-based regimen in an adult Wilms' tumor patient: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Male; Melphalan; Nephrectomy; Topotecan; Wilms Tumor; Young Adult | 2011 |
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Topics: Antineoplastic Agents; Cell Line, Tumor; Child; Drug Screening Assays, Antitumor; Etoposide; Humans; Melphalan; National Cancer Institute (U.S.); Sirolimus; United States; Vincristine | 2011 |
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
Topics: Acute Disease; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lung; Male; Melphalan; Middle Aged; Pneumonia; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Absorption measurements for broad beams of 1- and 2-million-volt X-rays.
Topics: Carmustine; Cytarabine; Etoposide; Melphalan; X-Rays | 1946 |
Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Etoposide; Female; Humans; Ifosfamide; Infant; Kaplan-Meier Estimate; Lomustine; Male; Melphalan; Mesna; Neuroblastoma; Pilot Projects; Risk Factors; Thoracic Neoplasms; Topotecan; Treatment Outcome | 2011 |
Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins.
Topics: Alkylating Agents; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cisplatin; Cytochromes c; Cytoprotection; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Isotretinoin; Melphalan; Membrane Potential, Mitochondrial; Mitochondria; Neuroblastoma; Nitrophenols; Piperazines; Protective Agents; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Sulfonamides; Topoisomerase Inhibitors; Tumor Suppressor Protein p53 | 2010 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Young Adult | 2011 |
ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Melphalan; Radiotherapy Dosage; Remission Induction; Second-Look Surgery; Spinal Neoplasms; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vincristine | 2011 |
FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Computer Simulation; Cyclophosphamide; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Etoposide; Female; Humans; Infant; Male; Melphalan; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Protein Binding | 2012 |
Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carmustine; Clinical Trials, Phase I as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Immunoconjugates; Lymphoma, Large-Cell, Anaplastic; Maintenance Chemotherapy; Male; Melphalan; Prednisone; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2012 |
Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Multivariate Analysis; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Young Adult | 2012 |
[Pulmonary Langerhans histiocytosis and Hodgkin's lymphoma].
Topics: Accidents, Traffic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchioles; Carmustine; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Female; Histiocytosis, Langerhans-Cell; Hodgkin Disease; Humans; Ifosfamide; Incidental Findings; Lung Diseases; Lymphatic Diseases; Marijuana Smoking; Melphalan; Methylprednisolone; Mitoguazone; Remission Induction; Smoking; Tomography, X-Ray Computed; Vinblastine; Vindesine; Vinorelbine; Young Adult | 2011 |
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine | 2011 |
Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous; Young Adult | 2012 |
Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Melphalan; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2012 |
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Young Adult | 2012 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2012 |
Selective ophthalmic arterial infusion of chemotherapeutic drugs for recurrent retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Cryotherapy; Electrophysiology; Electroretinography; Etoposide; Female; Humans; Infusions, Intra-Arterial; Melphalan; Neoplasm Recurrence, Local; Ophthalmic Artery; Retinal Neoplasms; Retinoblastoma; Treatment Outcome; Vincristine | 2012 |
[First case in Spain of bacteremia by Methylobacterium thiocyanatum from Hickmann catheter in an immunosuppressed patient with Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Biofilms; Bleomycin; Carmustine; Catheter-Related Infections; Central Venous Catheters; Cisplatin; Cross Infection; Cytarabine; Dacarbazine; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple, Bacterial; Equipment Contamination; Etoposide; Female; Gemcitabine; Gram-Negative Bacterial Infections; Hodgkin Disease; Humans; Immunocompromised Host; Melphalan; Methylobacterium; Prednisone; Ribotyping; Spain; Vinblastine | 2012 |
Intravenous chemoreduction or intra-arterial chemotherapy for cavitary retinoblastoma: long-term results.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Etoposide; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Infant; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Melphalan; Ophthalmic Artery; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vincristine | 2012 |
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Melphalan; Myeloablative Agonists; Neoplasm Metastasis; Prognosis; Sarcoma, Ewing; Stem Cell Transplantation; Vincristine; Young Adult | 2012 |
Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carmustine; Cisplatin; Combined Modality Therapy; Compassionate Use Trials; Crizotinib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Immunoconjugates; Lymphocyte Transfusion; Lymphoma, Large-Cell, Anaplastic; Male; Melphalan; Molecular Targeted Therapy; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Prednisone; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Remission Induction; Respiration, Artificial; Respiratory Insufficiency; Transplantation, Homologous; Vincristine | 2013 |
Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma.
Topics: Administration, Intravenous; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Injections, Intra-Arterial; Injections, Intraocular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Ophthalmic Artery; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Salvage Therapy; Topotecan; Treatment Outcome; Vincristine; Young Adult | 2013 |
Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Time Factors; Transplantation, Autologous; Treatment Outcome | 2013 |
Modified BEAM conditioning regimen in patients with Hodgkin and non-Hodgkin lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lomustine; Lymphoma, Non-Hodgkin; Melphalan | 2012 |
Successful allogeneic stem cell transplantation for Lennert lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Etoposide; Female; Humans; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Melphalan; Methotrexate; Middle Aged; Nitrosourea Compounds; Pharyngitis; Prednisolone; Recurrence; Rituximab; Salvage Therapy; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vincristine; Whole-Body Irradiation | 2013 |
Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cerebellar Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Medulloblastoma; Melphalan; Neoplasm Staging; Prognosis; Prospective Studies; Radiotherapy Dosage; Risk Factors; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Thiotepa; Transplantation, Autologous; Young Adult | 2013 |
The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP-Binding Cassette Transporters; Carboplatin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Etoposide; Humans; Isoquinolines; Ligands; Melphalan; Neuroblastoma; Receptors, GABA; Recurrence; RNA, Messenger | 2013 |
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Mucositis; Peripheral Blood Stem Cell Transplantation; Preoperative Care; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Young Adult | 2013 |
Bone marrow osteoblast vulnerability to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cell Line; Chemokine CXCL12; Collagen Type I; Collagen Type I, alpha 1 Chain; Etoposide; Extracellular Matrix; Hematopoietic Stem Cells; Humans; Melphalan; Mice; Osteoblasts; Osteocalcin; Osteopontin; Stem Cell Niche | 2013 |
Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carmustine; Chemoradiotherapy; Cisplatin; Cohort Studies; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Vinblastine; Young Adult | 2015 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult | 2013 |
Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Coculture Techniques; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Melphalan; Membrane Potential, Mitochondrial; Mesenchymal Stem Cells; Monocytes; Neuroblastoma; Receptors, Interleukin-6; STAT3 Transcription Factor; Up-Regulation | 2013 |
[Busulfan, cyclophosphamide and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma].
Topics: Adult; Busulfan; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Risk Factors; Transplantation, Autologous; Young Adult | 2013 |
Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2013 |
Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Myeloid Cells; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Thiotepa; Transplantation, Autologous; Young Adult | 2013 |
Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2013 |
Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; C-Reactive Protein; Carmustine; Case-Control Studies; Cytarabine; Etoposide; Febrile Neutropenia; Female; Fibroblast Growth Factor 7; Hematopoietic Stem Cell Transplantation; Humans; Inflammation; Intestinal Mucosa; Male; Melphalan; Middle Aged; Mucositis; Neutropenia; Young Adult | 2014 |
Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2014 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Outpatients; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2014 |
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Nitrosourea Compounds; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Autologous | 2014 |
The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Registries; Retrospective Studies | 2014 |
Radium beam therapy.
Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radium | 1951 |
Radium beam therapy at the Western Infirmary of Glasgow, 1938-48.
Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radium | 1951 |
Cobalt 60 beam therapy.
Topics: Carmustine; Cobalt; Cobalt Radioisotopes; Etoposide; Melphalan; Radioactivity; Radiotherapy | 1954 |
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Lymphoma, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Podophyllotoxin; Prednisone; Prognosis; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2015 |
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Chlorambucil; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Melphalan; Multicenter Studies as Topic; Neoplasm Staging; Prednisolone; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vincristine | 2014 |
The potential role of pretransplant MIBG diagnostic scintigraphy in targeted administration of 131I-MIBG accompanied by ASCT for high-risk and relapsed neuroblastoma: a pilot study.
Topics: 3-Iodobenzylguanidine; Carboplatin; Child; Child, Preschool; Disease-Free Survival; Etoposide; Female; Humans; Infant; Male; Melphalan; Neoplasm Recurrence, Local; Neuroblastoma; Pilot Projects; Prognosis; Prospective Studies; Radionuclide Imaging; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cisplatin; Combined Modality Therapy; Cytarabine; Drug Evaluation; Etoposide; Febrile Neutropenia; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Methylprednisolone; Middle Aged; Radionuclide Imaging; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Young Adult | 2014 |
Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lymphoma; Male; Melphalan; Middle Aged; Transplantation Conditioning; Young Adult | 2014 |
BEAM-conditioned autologous SCT improves the quality of response in Waldenström's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Waldenstrom Macroglobulinemia | 2014 |
Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2014 |
Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Etoposide; Female; Glioma; Humans; Liver Neoplasms; Melphalan; Mice, Inbred BALB C; Neuroblastoma; Podophyllotoxin; Radiation, Ionizing; Spermine | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Toxicity of tandem high-dose chemotherapy and autologous stem cell transplantation using carboplatin-thiotepa-etoposide and cyclophosphamide-melphalan regimens for malignant brain tumors in children and young adults.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Humans; Infant; Male; Melphalan; Retrospective Studies; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous; Young Adult | 2014 |
Risk of premature menopause after treatment for Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Child, Preschool; Cytarabine; Dacarbazine; Doxorubicin; England; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Infant; Melphalan; Menopause, Premature; Ovary; Poisson Distribution; Proportional Hazards Models; Radiotherapy Dosage; Risk Assessment; Surveys and Questionnaires; Vinblastine; Wales; Young Adult | 2014 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult | 2016 |
Children with relapsed or refractory nephroblastoma: favorable long-term survival after high-dose chemotherapy and autologous stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Dactinomycin; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kidney Neoplasms; Male; Melphalan; Neoplasm Recurrence, Local; Transplantation Conditioning; Vincristine; Wilms Tumor | 2014 |
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2015 |
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Registries; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 2015 |
Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Dog Diseases; Dogs; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Histiocytic Sarcoma; Melphalan; Methotrexate; Nimustine; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Vinblastine; Vincristine | 2015 |
Induction of centrosome amplification by formaldehyde, but not hydroquinone, in human lymphoblastoid TK6 cells.
Topics: Aneuploidy; Cell Line; Centrosome; Chromosome Aberrations; Dose-Response Relationship, Drug; Etoposide; Formaldehyde; Humans; Hydroquinones; Lymphocytes; Melphalan | 2015 |
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Topics: Adult; Aged; Aminocaproic Acid; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carmustine; Combined Modality Therapy; Cyclophosphamide; Erythropoietin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hemoglobins; Humans; Iron; Jehovah's Witnesses; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Transplantation, Autologous; Vitamin K 1; Young Adult | 2015 |
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Risk; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2015 |
High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Osteosarcoma; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2015 |
Clinical interpretation of residual uptake in 11C-methionine positron emission tomography after treatment of basal ganglia germ cell tumors: report of 3 cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Basal Ganglia; Carbon Radioisotopes; Child; Choriocarcinoma; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Cyclophosphamide; Disease-Free Survival; Etoposide; False Positive Reactions; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lateral Ventricles; Male; Melphalan; Methionine; Neoplasm Recurrence, Local; Neoplasm, Residual; Organoplatinum Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Supratentorial Neoplasms; Tissue Distribution; Young Adult | 2015 |
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2015 |
Cavernous angioma after chemotherapy for desmoplastic/nodular medulloblastoma associated with anhidrotic ectodermal dysplasia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cerebellar Neoplasms; Child, Preschool; Cisplatin; Cyclophosphamide; Ectodermal Dysplasia; Etoposide; Hemangioma, Cavernous, Central Nervous System; Humans; Infant; Intracranial Hemorrhages; Male; Medulloblastoma; Melphalan; Methotrexate; Neurosurgical Procedures; Peripheral Blood Stem Cell Transplantation; Vincristine | 2016 |
Fertility After Treatment With High Dose Melphalan in Women With Acute Myelogenous Leukemia.
Topics: Adolescent; Adult; Anthracyclines; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Fertility; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Myeloablative Agonists; Survivors; Transplantation Conditioning; Young Adult | 2016 |
Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Severity of Illness Index; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2016 |
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carmustine; Creatinine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Serum Albumin; Transplantation, Autologous; Treatment Outcome; Young Adult | 2015 |
Intraocular surgery with melphalan irrigation for vitreous hemorrhage in an only eye with retinoblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Combined Modality Therapy; Cryotherapy; Cyclophosphamide; Dacarbazine; Endotamponade; Etoposide; Humans; Infant; Male; Melphalan; Retinal Neoplasms; Retinoblastoma; Silicone Oils; Therapeutic Irrigation; Vincristine; Visual Acuity; Vitrectomy; Vitreous Hemorrhage | 2015 |
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Drug Evaluation; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Positron-Emission Tomography; Prospective Studies; Registries; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Young Adult | 2016 |
Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.
Topics: Adolescent; Antineoplastic Agents; Boston; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; Egypt; Etoposide; Humans; Infant; Infant, Newborn; Melphalan; Neuroblastoma; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2016 |
LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
Topics: Adolescent; Adult; Autografts; Carmustine; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lomustine; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Retrospective Studies; Survival Rate; Transplantation Conditioning; Young Adult | 2016 |
Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Carboplatin; Child; Child, Preschool; Critical Care; Databases, Factual; Etoposide; Female; Follow-Up Studies; Humans; Incidence; Infant; Length of Stay; Male; Melphalan; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Sepsis; Stem Cells; Transplantation Conditioning; United States | 2016 |
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Male; Melphalan; Recurrence; Transplantation Conditioning; Young Adult | 2016 |
Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Advanced unilateral retinoblastoma: a case of sparing enucleation treatment failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Etoposide; Eye Enucleation; Fluorescein Angiography; Humans; Infusions, Intra-Arterial; Intravitreal Injections; Magnetic Resonance Imaging; Male; Melphalan; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Seeding; Optic Nerve Neoplasms; Retinal Neoplasms; Retinoblastoma; Treatment Failure | 2016 |
Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Hypertension, Pulmonary; Infant; Kidney Diseases; Male; Melphalan; Mucositis; Myeloablative Agonists; Neuroblastoma; Pancytopenia; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Young Adult | 2016 |
A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lymphoma; Male; Melphalan; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2016 |
Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Febrile Neutropenia; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Nausea; Nitrosourea Compounds; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Chemotherapy-induced Dkk-1 expression by primary human mesenchymal stem cells is p53 dependent.
Topics: Cells, Cultured; Etoposide; Gene Knockdown Techniques; Humans; Intercellular Signaling Peptides and Proteins; Melphalan; Mesenchymal Stem Cells; Tumor Suppressor Protein p53 | 2016 |
First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of
Topics: Aftercare; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Etoposide; Humans; Infant; Infusions, Intra-Arterial; Infusions, Intravenous; Melphalan; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vision Disorders | 2017 |
Cryptococcus laurentii diarrhea post hematopoietic stem cell transplant.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carmustine; Cryptococcosis; Cryptococcus; Cytarabine; Diarrhea; Etoposide; Feces; Fluconazole; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Microbial Sensitivity Tests; Transplantation Conditioning; Transplantation, Autologous; Voriconazole | 2017 |
Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Case-Control Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Radioimmunotherapy; Retrospective Studies; Rituximab; Survival Analysis; Transplantation, Autologous; Young Adult | 2017 |
Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cryotherapy; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infusions, Intravenous; Intravitreal Injections; Laser Coagulation; Male; Melphalan; Neoplasm Seeding; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Salvage Therapy; Vincristine; Vitreous Body | 2017 |
Induced Aneugenic Effects in Mouse Oocytes In Vivo.
Topics: Aneugens; Aneuploidy; Animals; Cisplatin; Colchicine; Doxorubicin; Etoposide; Melphalan; Mice; Oocytes; Paclitaxel; Polyploidy | 2017 |
Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2018 |
The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Biopsy; Combined Modality Therapy; Doxorubicin; Etoposide; Factor X Deficiency; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Melphalan; Middle Aged; Remission Induction; Transplantation, Autologous | 2018 |
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Case-Control Studies; Cytarabine; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2018 |
Abdominal computed tomography angiography in post-transplantation sinusoidal obstruction syndrome associated with R-DHAOX/BEAM toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Computed Tomography Angiography; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Organoplatinum Compounds; Syndrome | 2018 |
Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine | 2018 |
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carmustine; Cost-Benefit Analysis; Cyclophosphamide; Cytarabine; Etoposide; Female; HIV Infections; Humans; Ifosfamide; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Staging; Retrospective Studies; Rituximab; Survival Analysis | 2018 |
BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2018 |
Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuximab Vedotin; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Kaplan-Meier Estimate; Male; Melphalan; Methylprednisolone; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Young Adult | 2018 |
Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Pneumonia; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2018 |
High-dose chemotherapy without whole lung radiation for refractory pulmonary metastases in an infant with stage IV favorable histology Wilms tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Etoposide; Humans; Infant; Kidney Neoplasms; Lung Neoplasms; Male; Melphalan; Wilms Tumor | 2018 |
High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2018 |
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2018 |
Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Carboplatin; Child; Child, Preschool; Databases, Factual; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Length of Stay; Male; Melphalan; Neuroblastoma; Stem Cell Transplantation | 2018 |
High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2019 |
Acute Complications After High-Dose Chemotherapy and Stem-Cell Rescue in Pediatric Patients With High-Risk Neuroblastoma Treated in Countries With Different Resources.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Carboplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Egypt; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Neuroblastoma; Stem Cell Transplantation; Transplantation Conditioning | 2018 |
Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Topics: Age Factors; Antineoplastic Agents; Area Under Curve; Body Weight; Carboplatin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Dosage Calculations; Etoposide; Female; Glomerular Filtration Rate; Humans; Infant; Kidney; Male; Melphalan; Models, Biological; Neuroblastoma | 2019 |
Nasoethmoidal Intestinal-Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti-Epidermal Growth Factor Receptor Therapy.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cetuximab; Cytarabine; ErbB Receptors; Etoposide; Genotype; Humans; Intestinal Neoplasms; Liquid Biopsy; Male; Melphalan; Paranasal Sinus Neoplasms | 2019 |
Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Semustine; Survival Rate; Transplantation Conditioning | 2019 |
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Young Adult | 2019 |
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Induction Chemotherapy; International Cooperation; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2019 |
Tandem high-dose chemotherapy with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin regimens for pediatric high-risk brain tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Male; Melphalan; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa; Topotecan; Transplantation, Autologous; Treatment Outcome | 2019 |
Strategy to minimize radiation burden in infants and high-risk medulloblastoma using intrathecal methotrexate and high-dose chemotherapy: A prospective registry study in Japan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Injections, Spinal; Male; Medulloblastoma; Melphalan; Methotrexate; Prognosis; Prospective Studies; Registries; Survival Rate | 2020 |
Hemophagocytic relapsed intramedullary plasmacytoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Bortezomib; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Magnetic Resonance Imaging; Melphalan; Neoplasm Recurrence, Local; Oligopeptides; Plasmacytoma; Positron Emission Tomography Computed Tomography; Pubic Bone; Rare Diseases; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2020 |
Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Oxaliplatin; Prednisone; Recurrence; Rituximab; Salvage Therapy; Transplantation, Autologous; Vincristine | 2020 |
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Prospective Studies; Retrospective Studies; Transplantation, Autologous | 2020 |
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Multivariate Analysis; Registries; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Treatment Outcome; Young Adult | 2020 |
Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infusions, Intra-Arterial; Infusions, Intravenous; Intraocular Pressure; Male; Melphalan; Middle Aged; Prognosis; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Survival Rate; Vincristine; Young Adult | 2020 |
Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Melphalan; Transplantation Conditioning; Transplantation, Autologous | 2020 |
BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Progression-Free Survival; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2020 |
Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neoplasm Staging; Neuroblastoma; Retrospective Studies; Transplantation, Autologous | 2020 |
Effects of cryotherapy on high-dose melphalan-induced oral mucositis in pediatric patients undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cryotherapy; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Neoplasms; Prognosis; Retrospective Studies; Stomatitis; Transplantation, Autologous; Young Adult | 2020 |
Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma-a retrospective study from the BSBMT (BEAM versus LEAM).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Humans; Lomustine; Lymphoma; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2021 |
Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Mitoxantrone; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Bendamustine-induced nephrogenic diabetes insipidus - A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Diabetes Insipidus, Nephrogenic; Diabetes Mellitus; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation, Autologous | 2022 |
BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Podophyllotoxin; Transplantation Conditioning | 2021 |
Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients' outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Neoplasm Recurrence, Local; Neutrophils; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Retrospective Studies; Transplantation, Autologous | 2022 |
[Safety and the short-term efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Retrospective Studies; Semustine; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2022 |
High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Comparison of CEAC, BEAM and IEAC conditioning regimens followed by autologous stem cell transplantation in peripheral T-cell lymphoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Peripheral; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2022 |
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
Topics: Antilymphocyte Serum; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin Heavy Chains; Melphalan; Multiple Sclerosis | 2022 |
Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Transplantation, Autologous | 2023 |
Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2023 |
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2023 |